Is there a real risk of bacterial infection in patients receiving targeted and biological therapies? | Enfermedades Infecciosas y Microbiología Clínica (English Edition)

array:23 ["pii" => "S2529993X22000879" "issn" => "2529993X" "doi" => "10.1016/j.eimce.2020.10.014" "estado" => "S300" "fechaPublicacion" => "2022-05-01" "aid" => "2328" "copyright" => "Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica" "copyrightAnyo" => "2020" "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Enferm Infecc Microbiol Clin. 2022;40:266-72" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:18 [ "pii" => "S2529993X22000399" "issn" => "2529993X" "doi" => "10.1016/j.eimce.2022.02.010" "estado" => "S300" "fechaPublicacion" => "2022-05-01" "aid" => "2461" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Enferm Infecc Microbiol Clin. 2022;40:273-4" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "Diagnosis at first sight" "titulo" => "Unexpected cause of ischemic lesions in an immunocompetent patient" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "273" "paginaFinal" => "274" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Causa inesperada de lesiones isquémicas en paciente inmunocompetente" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 984 "Ancho" => 905 "Tamanyo" => 66766 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "T1-weighted transverse slice showing significant inflammatory component of the right sinus and orbital structures with slight protrusion of the eyeball." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Antonio Bustos-Merlo, Antonio Rosales-Castillo, Virginia Sotorrío Simo" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Antonio" "apellidos" => "Bustos-Merlo" ] 1 => array:2 [ "nombre" => "Antonio" "apellidos" => "Rosales-Castillo" ] 2 => array:2 [ "nombre" => "Virginia" "apellidos" => "Sotorrío Simo" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0213005X21002214" "doi" => "10.1016/j.eimc.2021.06.020" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X21002214?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529993X22000399?idApp=UINPBA00004N" "url" => "/2529993X/0000004000000005/v1_202205140740/S2529993X22000399/v1_202205140740/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S2529993X22001022" "issn" => "2529993X" "doi" => "10.1016/j.eimce.2021.05.015" "estado" => "S300" "fechaPublicacion" => "2022-05-01" "aid" => "2435" "copyright" => "Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Enferm Infecc Microbiol Clin. 2022;40:262-5" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "Brief report" "titulo" => "First importations of SARS-CoV-2 P.1 and P.2 variants from Brazil to Spain and early community transmission" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "262" "paginaFinal" => "265" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Primeras importaciones de las variantes SARS-CoV-2 P.1 y P.2 de Brasil a Madrid y transmisión comunitaria" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1967 "Ancho" => 3500 "Tamanyo" => 824748 ] ] "descripcion" => array:1 [ "en" => "Phylogenetic relationship of SARS-CoV-2 based on the alignment of all P.1 (panel A) and P.2 sequences (panel B) from Brazil (completed (>29000bp) with high coverage (<1% Ns)) deposited in GISAID up to March 15, 2021 (714 and 477 samples respectively). Maximum likelihood unrooted tree displaying the genetic distance between all samples collected and the new presented in this study, colored by their lineage, was performed by a multi-alignment with mafft and IQ-TREE GTR+F+R2 mode with 1000 bootstrap replications. Reference for our sequences in GIDAID are: EPI_ISL_985404 (P.1), EPI_ISL_985408 (P.2), EPI_ISL_985409 (P.2), EPI_ISL_1233413 (P.2), EPI_ISL_1381872 (P.1), EPI_ISL_1477061 (P.1) and EPI_ISL_1647839 (P.2)." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Pedro J. Sola Campoy, Sergio Buenestado-Serrano, Laura Pérez-Lago, Cristina Rodriguez-Grande, Pilar Catalán, Cristina Andrés-Zayas, Luis Alcalá, Carmen Losada, Carla Rico-Luna, Patricia Muñoz, Darío García de Viedma" "autores" => array:12 [ 0 => array:2 [ "nombre" => "Pedro J." "apellidos" => "Sola Campoy" ] 1 => array:2 [ "nombre" => "Sergio" "apellidos" => "Buenestado-Serrano" ] 2 => array:2 [ "nombre" => "Laura" "apellidos" => "Pérez-Lago" ] 3 => array:2 [ "nombre" => "Cristina" "apellidos" => "Rodriguez-Grande" ] 4 => array:2 [ "nombre" => "Pilar" "apellidos" => "Catalán" ] 5 => array:2 [ "nombre" => "Cristina" "apellidos" => "Andrés-Zayas" ] 6 => array:2 [ "nombre" => "Luis" "apellidos" => "Alcalá" ] 7 => array:2 [ "nombre" => "Carmen" "apellidos" => "Losada" ] 8 => array:2 [ "nombre" => "Carla" "apellidos" => "Rico-Luna" ] 9 => array:2 [ "nombre" => "Patricia" "apellidos" => "Muñoz" ] 10 => array:2 [ "nombre" => "Darío" "apellidos" => "García de Viedma" ] 11 => array:1 [ "colaborador" => "on behalf of the Gregorio Marañón Microbiology-ID COVID 19 Study Group" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529993X22001022?idApp=UINPBA00004N" "url" => "/2529993X/0000004000000005/v1_202205140740/S2529993X22001022/v1_202205140740/en/main.assets" ] "en" => array:18 [ "idiomaDefecto" => true "cabecera" => "Review article" "titulo" => "Is there a real risk of bacterial infection in patients receiving targeted and biological therapies?" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "266" "paginaFinal" => "272" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Ivan Noreña, Mario Fernández-Ruiz, José María Aguado" "autores" => array:3 [ 0 => array:4 [ "nombre" => "Ivan" "apellidos" => "Noreña" "email" => array:1 [ 0 => "ivan.norena@lrz.uni-muenchen.de" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Mario" "apellidos" => "Fernández-Ruiz" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "José María" "apellidos" => "Aguado" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Teaching and Training Unit, Division of Infectious Diseases and Tropical Medicine, LMU University Hospital Munich, Munich, Germany" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Unit of Infectious Diseases, Hospital Universitario “12 de Octubre”, Instituto de Investigación Sanitaria Hospital “12 de Octubre” (imas12), Madrid, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "School of Medicine, Universidad Complutense. Madrid, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "¿Existe un riesgo real de infección bacteriana en pacientes que reciben terapias biológicas?" ] ] "textoCompleto" => "IntroductionOver the last twenty years, the introduction of targeted and biological therapies has revolutionized the treatment of solid cancer and hematological and inflammatory diseases. The increasing experience with these agents has allowed to estimate the associated risk of developing opportunistic infections, such as invasive aspergillosis, shingles or Pneumocystis jirovecii pneumonia.<a class="elsevierStyleCrossRef" href="#bib0290">1</a> Targeted and biologic therapies produce different blockages in the immune pathways involved in both the innate and adaptive responses related to the host-bacteria interaction, which could increase the susceptibility to severe bacterial infections.<a class="elsevierStyleCrossRef" href="#bib0295">2</a> Nevertheless, this specific risk has not yet been completely elucidated, and recommendations are mainly based on expert opinions.The present review summarizes the information concerning the risk and management of bacterial infection in patients receiving targeted and biological therapies. We performed a computer-based MEDLINE (National Library of Medicine, Bethesda, MD) search with no temporal or language restrictions, using the MeSH terms appropriate for each agent (always including “infection” or “infectious complications”) to capture the literature pertaining to the subject. Particular attention was given to the safety data reported across pivotal randomized controlled trials (RCTs) and relevant post-marketing surveillance studies. The references of selected articles were also examined for additional related references. We have also collected information from the recommendations issued by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH).<a class="elsevierStyleCrossRefs" href="#bib0295">2–9</a>Which factors related to bacterial infections have to be considered before the initiation of targeted and biological therapies?First, we should consider that many autoimmune and inflammatory diseases intrinsically confer an increased baseline susceptibility to bacterial pathogens. Therefore, those patients with severe underlying conditions could be at additional risk once the therapy is initiated.<a class="elsevierStyleCrossRef" href="#bib0335">10</a><a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a> depicts some risk factors that could increase concomitantly the risk of bacterial infection in patients with rheumatic diseases receiving targeted therapies.<a class="elsevierStyleCrossRefs" href="#bib0340">11,12</a> The presence of previous debilitating chronic disorders (e.g. chronic obstructive pulmonary disease, interstitial lung disease or chronic kidney disease),<a class="elsevierStyleCrossRefs" href="#bib0340">11,12</a> the previous occurrence of serious infections, and high cumulative doses of corticosteroids also act as contributing factors. Despite the paucity of supporting data, numerous guidelines recommend not to initiate any biological therapy in patients with a concomitant severe active infection (which is usually defined as that requiring intravenous treatment or hospitalization).<a class="elsevierStyleCrossRef" href="#bib0340">11</a><elsevierMultimedia ident="tbl0005"></elsevierMultimedia>What is the risk of developing a bacterial infection with the different targeted and biological agents?We have reviewed the existing experience by classifying the biological agents into six large categories according to their intimate mechanism of action (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>).<elsevierMultimedia ident="tbl0010"></elsevierMultimedia>Soluble immune effector molecules and pro-inflammatory cytokines: anti-TNF-α agentsMost relevant data related to the specific risk of bacterial infection in patients receiving targeted and biological agents are derived from the experience with the therapeutic blockade of tumor necrosis factor (TNF)-α in rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). This theoretical background is often extensible to other indications with a more limited clinical experience. Curtis et al. analyzed the incidence of common bacterial infections with anti-TNF-α agents (abatacept, rituximab, infliximab, etanercept and adalimumab) in a large cohort (n=3111) of RA patients from the US Veterans Health Administration between 1998 and 2011, reporting high rates for pneumonia (37%), cellulitis and soft tissue infection (22%), and urinary tract infection (9%). In this study, the use of abatacept was associated with a higher rate of bacterial infection-related hospitalization, although the multivariate analysis revealed no differences across different agents. The risk of infection was greater among patients receiving corticosteroids (daily prednisone dose>7.5mg or equivalent) and for those in the highest quartile of C-reactive protein levels and erythrocyte sedimentation rate (as compared to the lowest quartile).<a class="elsevierStyleCrossRef" href="#bib0345">12</a> More recently, Carrara et al. estimated in an Italian cohort of RA patients (n=4656) incidence rates for pneumonia, bloodstream infection, cellulitis and septic arthritis of 2.95, 2.51, 1.30 and 1.06 episodes per 1000 patient-years, respectively. Abatacept seemed to be protective for severe infection-related hospitalization as compared to etanercept, while the use of other agents was not shown to increase the infection risk compared with this anti-TNF-α agent. Additional risk factors included the occurrence of severe infection within the previous year and high corticosteroid doses.<a class="elsevierStyleCrossRef" href="#bib0350">13</a> A Japanese cohort found a higher incidence of pulmonary infection among patients receiving adalimumab, with no differences between different biological agents in the overall risk of infection. These authors also found a significantly increased risk related to older age, RA severity, low body mass index, and presence of chronic comorbidities such as diabetes.<a class="elsevierStyleCrossRef" href="#bib0355">14</a> A network meta-analysis for severe infection in RA patients found that standard- (odds ratio [OR]: 1.31; 95% confidence interval [CI]: 1.09–1.58) and high-dose (OR: 1.90; 95% CI: 1.50–2.39) therapy with biological agents were both associated with a higher risk for severe infection, although such difference was not significant for methotrexate (MTX) naïve and anti-TNF-α experienced patients.<a class="elsevierStyleCrossRef" href="#bib0360">15</a> In a meta-analysis of IBD patients receiving different anti-TNF-α agents and other therapies (vedolizumab or natalizumab), the incidence of serious infection was not significantly increased as compared to placebo (OR: 0.89; 95% CI: 0.71–1.12). Nevertheless, the overall risk of infection was higher in those patients on biologic agents (OR: 1.19; 95% CI: 1.10–1.29).<a class="elsevierStyleCrossRef" href="#bib0365">16</a> In summary, there is limited evidence suggesting an increase in the risk of bacterial infection with the use of anti-TNF-α agents. Of note, infections occur most frequently within the first year since the initiation of therapy.<a class="elsevierStyleCrossRef" href="#bib0370">17</a>Agents targeting interleukins, immunoglobulins and complement factorsTherapy with interleukin (IL)-1-targeted agents has been shown to be associated with a moderate increase in the risk of bacterial infection, mainly in form of respiratory, urinary tract and skin and skin structure infections.<a class="elsevierStyleCrossRefs" href="#bib0375">18,19</a> The reported incidence of serious infection is 5.4 episodes per 100 patient-years and seems to be increased among older patients with previous chronic diseases.<a class="elsevierStyleCrossRef" href="#bib0385">20</a> IL-6/IL-6R-targeted agents are associated with an increase in the risk of bacterial infection comparable to that observed with anti-TNF-α therapies, with pneumonia, urinary tract infection and cellulitis as the most commonly reported events.<a class="elsevierStyleCrossRefs" href="#bib0390">21,22</a> The pooled estimate for serious infection in phase 3 and extension RCTs is 4.9 episodes per 100 patient-years,<a class="elsevierStyleCrossRef" href="#bib0400">23</a> with higher rates in population-based studies (9.0 episodes per 100 patient-years).<a class="elsevierStyleCrossRef" href="#bib0405">24</a> It is important to note that most of the available experience with IL-6 blockade is restricted to tocilizumab, with limited data for sarilumab or siltuximab.Phase 2 and 3 RCTs evaluating the use of IL-17-targeted agents in patients with psoriasis, ankylosing spondylitis and psoriatic arthritis showed a minor increase in the risk of bacterial infection (2.4 episodes of serious infection per 100 patient-years), usually mild to moderate in severity. Upper respiratory and urinary tract infections were the most common syndromes, whereas cellulitis was the predominant serious infection.<a class="elsevierStyleCrossRefs" href="#bib0410">25,26</a> IL-12/23-targeted agents have not been associated with a significant increase in the risk of bacterial infection.<a class="elsevierStyleCrossRef" href="#bib0420">27</a>Eculizumab, a humanized monoclonal antibody targeting and preventing cleavage of the terminal complement component C5, notably predisposes to infections due to Neisseria spp., with a 10,000-fold increased risk for meningococcal infection. In addition, this agent has been associated with a significant increase in the risk of respiratory tract infection as compared to placebo.<a class="elsevierStyleCrossRef" href="#bib0305">4</a>Cell-surface receptors and associated signaling pathwaysA large meta-analysis pooling data from 41 RCTs and more than 30,000 patients with various cancer types (mostly colorectal carcinoma) that received vascular endothelial growth factor (VEGF)-targeted agents<a class="elsevierStyleCrossRef" href="#bib0425">28</a> concluded that the use of bevacizumab significantly increased the incidence of infection of any grade (relative risk [RR]: 1.45; 95% CI: 1.27–1.66) and serious infection (RR: 1.59; 95% CI: 1.42–1.79). In this meta-analysis, the infection risk associated to bevacizumab seemed to be mostly linked to the occurrence of febrile neutropenia, fistulae or abscesses, and pneumonia, but not sepsis or colitis.<a class="elsevierStyleCrossRef" href="#bib0425">28</a>Therapy with VEGF tyrosine kinase inhibitors does not increase the risk of infection.<a class="elsevierStyleCrossRef" href="#bib0430">29</a> The use of anti-VEGFR2 monoclonal antibodies (ramucirumab) is likely associated with a risk increase similar to that observed for VEGF-targeted agents, including the role of drug-induced neutropenia and gastrointestinal perforation as contributing factors.<a class="elsevierStyleCrossRefs" href="#bib0435">30,31</a>The use of epidermal growth factor receptor (EGFR)-targeted agents is associated with a meaningful increase in the risk of infection, mainly as a result of neutropenia and secondary infection in cases of severe papulopustular rash, with Staphylococcus aureus as a remarkable causative microorganism in skin and skin structure infections.<a class="elsevierStyleCrossRefs" href="#bib0445">32,33</a>Therapy with monoclonal antibodies targeting the human epidermal growth factor receptor 2 (ErbB2/HER2) might be associated with a minor increase in the risk of infection. However, the biologic rationale and clinical evidence supporting this association are weak.<a class="elsevierStyleCrossRef" href="#bib0455">34</a> Finally, ErbB receptor tyrosine kinase-targeted agents (including either selective EGFR/HER1 and/or ErbB2/HER2 inhibitors or pan-ErbB inhibitors) does not meaningfully increase the rate of bacterial infection.<a class="elsevierStyleCrossRef" href="#bib0310">5</a>Intracellular signaling pathways (tyrosine kinase and mTOR inhibitors)With some exceptions, this family of biologic agents does not show a significant increase in the susceptibility to bacterial pathogens.<a class="elsevierStyleCrossRef" href="#bib0315">6</a> Ibrutinib (a Bruton's tyrosine kinase [BTK] inhibitor) exhibited a modest increase in the risk of bacterial infection. Pneumonia is observed mainly in the presence of neutropenia, whereas about 10% of patients developed urinary tract infections.<a class="elsevierStyleCrossRefs" href="#bib0460">35,36</a> The risk is influenced by other factors like additional immunosuppressive drugs or previous immune disorders related to the underlying B-cell malignancies.Janus kinase (JAK) inhibitors are associated with a considerable increase in the risk of infection. Indeed, urinary tract infection, pneumonia, and septic shock were described for patients on ruxolitinib (a potent oral JAK1/JAK2 inhibitor) in rates of 24.6%, 13.1% and 7.9%, respectively, in one pivotal RCT for the treatment of myelofibrosis. Surprisingly, the long-term follow-up revealed a decrease in the incidence of infection, presumably resulting from the stabilization of the underlying disease with resolution of cytopenias.<a class="elsevierStyleCrossRef" href="#bib0470">37</a>A meta-analysis evaluating the use of mammalian target of rapamycin (mTOR) inhibitors in 4,097 cancer patients from 12 RCTs (8 with everolimus and 3 with temsirolimus) reported an increased risk of infection (overall incidence of all-grade infection of 25.0%; 95% CI: 16.7–35.9%), including fatal outcomes due to sepsis and pneumonia. Sub-group analysis revealed heterogeneity across different tumor types, with lower risks for patients with giant cell astrocytoma, breast cancer and angiomyolipoma, and higher risks for those with renal cell carcinoma, lymphomas or neuroendocrine tumors.<a class="elsevierStyleCrossRef" href="#bib0475">38</a> The variations in dose regimens are relevant in explaining these findings as compared to the more favorable safety profile observed among solid organ transplant recipients.<a class="elsevierStyleCrossRef" href="#bib0315">6</a>BCR-ABL tyrosine kinase inhibitors, BRAF/MEK kinase inhibitors, and PI3K inhibitors do not seem to increase the risk of serious bacterial infection, whereas limited information is still available for BCL-2 inhibitors.<a class="elsevierStyleCrossRef" href="#bib0315">6</a>Agents targeting lymphoid or myeloid cells surface antigensIn pivotal RCTs, mostly limited to blinatumomab, therapy with CD19-targeted agents does not show a significant increase in the risk of bacterial infection compared with conventional chemotherapy, with overall rates comparable to those expected in patients undergoing treatment for relapsed or refractory acute lymphoblastic leukemia.<a class="elsevierStyleCrossRef" href="#bib0480">39</a> Of note, the need for continuous intravenous infusion for 4 weeks in the blinatumomab regimen explains the elevated rate of catheter-associated bloodstream infection in the RCTs evaluating this first-in-class bispecific T-cell engager, with rates ranging from 2.2% to 11%.<a class="elsevierStyleCrossRefs" href="#bib0485">40,41</a> Careful management of intravenous lines is therefore warranted to minimize this risk. Clinicians caring for patients receiving such therapy should be also aware of the associated risk of hypogammaglobulinemia (HGG), which is associated with a well-established increased susceptibility to encapsulated bacteria such as Streptococcus pneumoniae.<a class="elsevierStyleCrossRef" href="#bib0495">42</a>Infection prevails as the most common non-hematological adverse effects of anti-CD20 monoclonal antibodies, including severe respiratory tract infection. Separate meta-analysis in lymphoma and RA do not show a significant increase in the risk of bacterial infection.<a class="elsevierStyleCrossRefs" href="#bib0500">43,44</a> Nevertheless, in a French cohort of patients with immune thrombocytopenia, the incidence of serious bacterial infections was 6.3 episodes per 100 patient-years, and as high as 100.5 episodes per 100 patient-years for non-serious infections. Pneumonia was the most frequently reported syndrome (42.8%), with gastrointestinal and urinary tract infections as other common infections.<a class="elsevierStyleCrossRef" href="#bib0510">45</a> Second- and third-generation anti-CD20 monoclonal antibodies could also increase the risk of bacterial infection, although this risk is determined by the presence of concomitant comorbidities, previous and concomitant immunosuppressive therapies, and the long-term occurrence of sever HGG.<a class="elsevierStyleCrossRef" href="#bib0320">7</a>The use of alemtuzumab (CD52-targeted agent) for different diseases shows a variable risk of bacterial infection explained in part by differences in dose regiments and the presence of previous immunosuppression. Overall, bacterial infections are higher in some scenarios such as cutaneous lymphoma, with an incidence rate of 23.3 episodes per 100 patient-years.<a class="elsevierStyleCrossRef" href="#bib0515">46</a>Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators, and proteasome inhibitorsThe available data from pivotal RCTs suggest that CTLA-4 (ipilimumab or tremelimumab) or PD-1/PD-L1 blockade (nivolumab or atezolizumab) is not intrinsically associated with an increase in the risk of infection.<a class="elsevierStyleCrossRefs" href="#bib0520">47–51</a> Nevertheless, cancer patients receiving immune checkpoint inhibitors may develop immune-related adverse events that may entail additional immunosuppressive therapy (such as corticosteroids or anti-TNF-α agents) impacting the susceptibility to bacterial pathogens (9). A systematic review in IBD found that patients treated with vedolizumab (an α4-integrin-targeted monoclonal antibody) experienced a moderate increase in the incidence of serious bacterial infections and surgical site infections compared to placebo.<a class="elsevierStyleCrossRef" href="#bib0545">52</a>Pneumonia is a common bacterial infection among patients with multiple myeloma (MM) treated with proteasome inhibitors (PIs), but data do not seem to support a higher risk weighed with comparator therapies. Of note, untreated MM patients already face an increased incidence of respiratory tract infections (including pneumonia) due to the underlying impairment of humoral immune responses. However, this susceptibility seems to be influenced by the use of PIs in the induction regimen.<a class="elsevierStyleCrossRef" href="#bib0550">53</a>Should biologic therapies be discontinued while treating a bacterial infection? When should they be reintroduced?Currently, studies evaluating these questions are lacking, and there is no clear evidence to guide the optimal management of bacterial infections in patients receiving biologic agents. Nevertheless, most guidelines concur on the need of discontinuing therapy in the presence of serious bacterial infection, to be reintroduced only once the infection has completely resolved. The decision should ideally be taken on a case-by-case basis by an experienced physician since, in some situations, the abrupt withdrawal of therapy can induce a flare of the underlying autoinflammatory disorder<a class="elsevierStyleCrossRef" href="#bib0340">11</a> or negatively impact the prognosis of the underlying disease. Indeed, it has been reported an increased risk of progression among patients with chronic lymphocytic leukemia in which the BTK inhibitor ibrutinib has to be discontinued.<a class="elsevierStyleCrossRef" href="#bib0555">54</a>Should asymptomatic bacteriuria be treated in patients receiving biological therapies?No studies have addressed whether patients receiving biologic therapies should be systematically screened and treated for asymptomatic bacteriuria. A case–control study performed in women with autoimmune rheumatic diseases reported no differences in the incidence of either asymptomatic or symptomatic urinary tract infection compared with the control group.<a class="elsevierStyleCrossRef" href="#bib0560">55</a> More data are needed to establish the management in this population, although systematic treatment would not be indicated, in line with other clinical scenarios in which no apparent benefit from this strategy has been demonstrated.<a class="elsevierStyleCrossRefs" href="#bib0565">56,57</a>What prevention strategies are required to prevent bacterial infections in patients receiving biological therapies?Clear recommendations aimed at minimizing the risk of bacterial infection linked to the use of the different families of biological and targeted agents are mostly lacking, except for some specific agents. As mentioned above, in view of the increased risk of N. meningitidis infection with eculizumab use, meningococcal vaccination must be assured before the initiation of therapy.<a class="elsevierStyleCrossRef" href="#bib0305">4</a> Vaccination against pneumococcal disease and Haemophylus influenzae type B should be provided according to current guidelines, and are recommended for various biologic targeted agents mentioned previously<a class="elsevierStyleCrossRefs" href="#bib0300">3,11</a> (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>). In other specific scenarios, antibiotic prophylaxis is recommended, as occurs in patients on EGFR targeted-agents who should receive oral doxycycline to prevent skin infections.<a class="elsevierStyleCrossRef" href="#bib0315">6</a> However, it should be emphasized that there is no clear evidence to support such practices, and any potential benefit must be always balanced against the well-defined risk of inducing antimicrobial resistance, as observed in neutropenic patients.ConclusionBacterial infections in patients on targeted and biologic therapies have a variable incidence depending on the agent used, with this risk being influenced by contributing factors such as previous comorbidities, the activity of the underlying condition, or the receipt of additional immunosuppressive therapy. There are few specific recommendations concerning the management and prevention of bacterial infections in these patient populations. The proven risk of invasive infections due to encapsulated bacteria clearly supports meningococcal and pneumococcal vaccination among patients treated with eculizumab and anti-CD20 agents. Nonetheless, evidence is mostly lacking for therapies involving interleukins and other soluble mediators, and no guidance may be provided for newer agents even in the presence of a theoretical infection risk (such as that potentially resulting from the blockade of the pro-inflammatory cytokines IL-1β or IL-6). In addition, no risk thresholds have been established to define in which patient subgroups interventions should be implemented. Multicenter post-marketing surveillance with granular information on the type and severity of infection, open-label extension studies and other sources of real-world data are necessary to elucidate the safety profile of these therapies, with the ultimate aim to define specific interventions if significant risk signals emerge.Funding sourcesThis research was supported by Plan Nacional de I+D+I 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Spanish Ministry of Science and Innovation, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0002) – co-financed by the European Development Regional Fund (EDRF) “A way to achieve Europe”. M.F.R. holds a research contract “Miguel Servet” (CP 18/00073) from the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III.Conflict of interestThe authors have no conflicts of interests to disclose." "textoCompletoSecciones" => array:1 [ "secciones" => array:13 [ 0 => array:3 [ "identificador" => "xres1709481" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1512047" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres1709480" "titulo" => "Resumen" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0010" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1512048" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "What is the risk of developing a bacterial infection with the different targeted and biological agents?" "secciones" => array:6 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Soluble immune effector molecules and pro-inflammatory cytokines: anti-TNF-α agents" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "Agents targeting interleukins, immunoglobulins and complement factors" ] 2 => array:2 [ "identificador" => "sec0025" "titulo" => "Cell-surface receptors and associated signaling pathways" ] 3 => array:2 [ "identificador" => "sec0030" "titulo" => "Intracellular signaling pathways (tyrosine kinase and mTOR inhibitors)" ] 4 => array:2 [ "identificador" => "sec0035" "titulo" => "Agents targeting lymphoid or myeloid cells surface antigens" ] 5 => array:2 [ "identificador" => "sec0040" "titulo" => "Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators, and proteasome inhibitors" ] ] ] 6 => array:2 [ "identificador" => "sec0045" "titulo" => "Should biologic therapies be discontinued while treating a bacterial infection? When should they be reintroduced?" ] 7 => array:2 [ "identificador" => "sec0050" "titulo" => "Should asymptomatic bacteriuria be treated in patients receiving biological therapies?" ] 8 => array:2 [ "identificador" => "sec0055" "titulo" => "What prevention strategies are required to prevent bacterial infections in patients receiving biological therapies?" ] 9 => array:2 [ "identificador" => "sec0060" "titulo" => "Conclusion" ] 10 => array:2 [ "identificador" => "sec0065" "titulo" => "Funding sources" ] 11 => array:2 [ "identificador" => "sec0070" "titulo" => "Conflict of interest" ] 12 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2020-08-13" "fechaAceptado" => "2020-10-06" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1512047" "palabras" => array:5 [ 0 => "Bacterial infection" 1 => "Targeted and biological therapies" 2 => "Immunosuppression" 3 => "Risk" 4 => "Incidence" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1512048" "palabras" => array:5 [ 0 => "Infección bacteriana" 1 => "Terapias biológicas" 2 => "Inmunosupresión" 3 => "Riesgo" 4 => "Incidencia" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "Over the past decades, the advent of targeted and biological therapies has revolutionized the management of cancer and autoimmune, hematological and inflammatory conditions. Although a large amount of information is now available on the risk of opportunistic infections associated with some of these agents, the evidence regarding the susceptibility to bacterial infections is more limited. Biological agents have been shown to entail a variable risk of bacterial infections in pivotal randomized clinical trials and post-marketing studies. Recommendations on risk minimization strategies and therapeutic interventions are therefore scarce and often based on expert opinion, with only a few clear statements for some particular agents (i.e. meningococcal vaccination for patients receiving eculizumab). In the present review the available information regarding the incidence of and risk factors for bacterial infection associated with the use of different groups of biological agents is summarized according to their mechanisms of action, and recommendations based on this evidence are provided. Additional information coming from clinical research and real-world studies is required to address unmet questions in this emerging field." ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "La introducción de terapias dirigidas y biológicas ha revolucionado a lo largo de las últimas décadas el tratamiento del cáncer y de las enfermedades autoinmunes, hematológicas e inflamatorias. Si bien existe abundante información acerca del exceso de riesgo de infección oportunista vinculado a algunos de estos agentes, la evidencia disponible sobre el riesgo de infección bacteriana específicamente es más limitada. En el marco de los ensayos clínicos pivotales y de estudios poscomercialización se ha demostrado un riesgo variable de infección bacteriana asociada al uso de terapias biológicas. Por ese motivo las recomendaciones para su minimización y abordaje terapéutico son escasas, y a menudo basadas en la opinión de expertos, con tan solo algunos escenarios de alto riesgo claramente establecidos para ciertos agentes (como la recomendación de vacunación anti-meningocócica en pacientes tratados con eculizumab). En la presente revisión se actualiza la información disponible respecto a la incidencia de infección bacteriana relacionada con las diferentes familias terapéuticas según su mecanismo de acción y sus factores de riesgo, aportándose igualmente algunas recomendaciones basadas en esta evidencia. Se requieren más estudios de investigación clínica en vida real para aclarar las preguntas sin resolver en este novedoso campo." ] ] "multimedia" => array:2 [ 0 => array:9 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "fuente" => "Adapted from Teixeira L et al.<a class="elsevierStyleCrossRef" href="#bib0340">11</a>" "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "COPD: chronic obstructive pulmonary disease, DMARDs: disease modifying anti-rheumatic drugs, RA: rheumatoid arthritis." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Specific syndromes \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Risk factors \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Upper or lower respiratory infections \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Advanced ageCOPD/asthmaDiabetes mellitusHeart diseaseSmoking \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Urinary tract infections \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Age≥65 yearsConcomitant therapy with corticosteroid (daily prednisone dose>5–10mg or equivalent) or DMARDsDisease duration>10 yearsDiabetes mellitusHeart diseaseChronic renal diseaseRecurrent infectionsCharlson comorbidity index≥2Hypogamaglobulinemia (in patients treated with anti-CD-20 agents)COPD/asthmaSmoking \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Skin and skin structure infections \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Advanced ageDiabetes mellitusHistory of previous skin and skin structure infectionsCorticosteroid therapy (daily prednisone dose>10mg or equivalent) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Osteoarticular infections \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Advanced ageProsthesisOpportunistic infectionsCorticosteroid therapy (daily prednisone dose>10mg or equivalent)Existence of extra-articular RA manifestationsB-cell depletion \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Disseminated infection \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Advanced ageLongstanding rheumatic diseaseHistory of previous infectionsConcomitant therapy with DMARDs and glucocorticoids \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab2903187.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Risk factors for the occurrence of bacterial infections in patients with rheumatic diseases receiving biological therapy." ] ] 1 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at2" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "Hib: Haemophilus influenzae type b; CRBSI: Catheter related bloodsttream infection." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Therapeutic group \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Specific targeted agents \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Bacterial infection risk \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Prevention strategies \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Agents targeting pro-inflammatory cytokines \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">TNF-α-targeted agents \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Moderate to high<a class="elsevierStyleCrossRef" href="#tblfn0005">a</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pneumococcal vaccination \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="7" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Agents targeting interleukins, immunoglobulins and complement factors</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IL-1-targeted agents \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Moderate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pneumococcal vaccination \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IL-5-targeted agents \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not increased \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IL-6/IL-6R-targeted agents \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Moderate to high \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pneumococcal vaccination \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IL-12/23 p40-targeted agents \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not increased \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IL-17-targeted agents \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mild \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not defined \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IgE-targeted agents \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not increased \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">C5-targeted agents \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">High to specific bacteria \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Menigococcal, pneumococcal and Hib vaccination \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Cell surface receptors and associated signaling pathways</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">VEGF-targeted agents \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Moderate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not defined \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">VEGFR tyrosine kinase inhibitors \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Moderate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not defined \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">EGFR -targeted agents \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">High \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Doxycycline prophylaxis \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HER2/neu-targeted agents Inhibitors of ErbB tyrosine kinase family \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mild \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not defined \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not increased \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="8" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Intracellular signaling pathways (tyrosine kinase and mTOR inhibitors)</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">BRAF inhibitors \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not increased \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">MEK inhibitors \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not increased \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">PI3K inhibitors \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not increased \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">mTOR inhibitors \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">High<a class="elsevierStyleCrossRef" href="#tblfn0010">b</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pneumococcal vaccination \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Janus kinase (JAK) inhibitors \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">High \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pneumococcal vaccination \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">BCR/ABL tyrosine kinase inhibitors \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not increased \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Antiapoptotic protein Bcl-2- targeted agents \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not established \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Bruton's tyrosine kinase inhibitors \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">High \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pneumococcal vaccination \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="10" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Agents targeting lymphoid or myeloid cells surface antigens</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CD19-targeted agents \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Moderate (CRBSI) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not defined \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CD20-targeted agents \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Moderate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pneumococcal vaccination \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CD22-targeted agents \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not increased \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CD30-targeted agents \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not increased \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CD33-targeted agents \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not established \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CD38-targeted agents \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mild \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not defined \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CD40-targeted agents \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mild \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not defined \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SLAMF7-targeted agents \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Moderate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not defined \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CD52-targeted agents \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Moderate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not defined \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CCR4-targeted agents \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not increased \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not defined \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="6" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators, and proteasome inhibitors</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">PD-1/PD-L1-targeted agents \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not increased<a class="elsevierStyleCrossRef" href="#tblfn0015">c</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Related to additional immunosuppression \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CTLA-4-targeted agents \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not increased<a class="elsevierStyleCrossRef" href="#tblfn0015">c</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">α4-integrins-targeted agents \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Moderate<a class="elsevierStyleCrossRef" href="#tblfn0020">d</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not defined \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Proteasome inhibitors \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Moderate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pneumococcal vaccination \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">LFA-3-targeted agents \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not increased \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Sphingosine-1-phosphate receptor \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not increased \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab2903188.png" ] ] ] "notaPie" => array:4 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "Conflicting data." ] 1 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "b" "nota" => "Dose-dependent (higher for cancer patients that for solid organ transplant recipients." ] 2 => array:3 [ "identificador" => "tblfn0015" "etiqueta" => "c" "nota" => "Risk may be increased due to additional immunosuppression used to treat immune-related adverse events." ] 3 => array:3 [ "identificador" => "tblfn0020" "etiqueta" => "d" "nota" => "Specifically vedolizumab." ] ] ] "descripcion" => array:1 [ "en" => "Bacterial infection risk associated to different families of targeted and biological agents and proposed prevention strategies." ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:57 [ 0 => array:3 [ "identificador" => "bib0290" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Screening for cervical and breast cancer among women with inflammatory bowel disease: a population-based study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "H. Singh" 1 => "Z. Nugent" 2 => "A.A. Demers" 3 => "C.N. Bernstein" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Inflamm Bowel Dis" "fecha" => "2011" "volumen" => "17" "paginaInicial" => "1741" "paginaFinal" => "1750" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0295" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the Safety of targeted and biological therapies: an Infectious Diseases perspective (Introduction)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Fernández-Ruiz" 1 => "Y. Meije" 2 => "O. Manuel" 3 => "H. Akan" 4 => "J. Carratalà" 5 => "J.M. Aguado" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.cmi.2018.01.029" "Revista" => array:8 [ "tituloSerie" => "Clin Microbiol Infect" "fecha" => "2018" "volumen" => "24" "numero" => "Suppl. 2" "paginaInicial" => "S2" "paginaFinal" => "S9" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29427801" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1064748118303269" "estado" => "S300" "issn" => "10647481" ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0300" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.W. Baddley" 1 => "F. Cantini" 2 => "D. Goletti" 3 => "J.J. Gómez-Reino" 4 => "E. Mylonakis" 5 => "R. San-Juan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.cmi.2017.12.025" "Revista" => array:7 [ "tituloSerie" => "Clin Microbiol Infect" "fecha" => "2018" "volumen" => "24" "numero" => "Suppl. 2" "paginaInicial" => "S10" "paginaFinal" => "S20" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29459143" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0305" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K.L. Winthrop" 1 => "X. Mariette" 2 => "J.T. Silva" 3 => "E. Benamu" 4 => "L.H. Calabrese" 5 => "A. Dumusc" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.cmi.2018.02.002" "Revista" => array:7 [ "tituloSerie" => "Clin Microbiol Infect" "fecha" => "2018" "volumen" => "24" "numero" => "Suppl. 2" "paginaInicial" => "S21" "paginaFinal" => "S40" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29447987" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0310" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Cell surface receptors and associated signaling pathways)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "J. Aguilar-Company" 1 => "M. Fernández-Ruiz" 2 => "R. García-Campelo" 3 => "A.C. Garrido-Castro" 4 => "I. Ruiz-Camps" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.cmi.2017.12.027" "Revista" => array:7 [ "tituloSerie" => "Clin Microbiol Infect" "fecha" => "2018" "volumen" => "24" "numero" => "Suppl. 2" "paginaInicial" => "S41" "paginaFinal" => "S52" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29426804" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0315" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Reinwald" 1 => "J.T. Silva" 2 => "N.J. Mueller" 3 => "J. Fortún" 4 => "C. Garzoni" 5 => "J.W. de Fijter" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.cmi.2018.02.009" "Revista" => array:7 [ "tituloSerie" => "Clin Microbiol Infect" "fecha" => "2018" "volumen" => "24" "numero" => "Suppl. 2" "paginaInicial" => "S53" "paginaFinal" => "S70" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29454849" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0320" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Mikulska" 1 => "S. Lanini" 2 => "C. Gudiol" 3 => "L. Drgona" 4 => "G. Ippolito" 5 => "M. Fernández-Ruiz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.cmi.2018.02.003" "Revista" => array:7 [ "tituloSerie" => "Clin Microbiol Infect" "fecha" => "2018" "volumen" => "24" "numero" => "Suppl. 2" "paginaInicial" => "S71" "paginaFinal" => "S82" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29447988" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0325" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "L. Drgona" 1 => "C. Gudiol" 2 => "S. Lanini" 3 => "B. Salzberger" 4 => "G. Ippolito" 5 => "M. Mikulska" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.cmi.2018.03.022" "Revista" => array:7 [ "tituloSerie" => "Clin Microbiol Infect" "fecha" => "2018" "volumen" => "24" "numero" => "Suppl. 2" "paginaInicial" => "S83" "paginaFinal" => "S94" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29572070" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0330" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. Redelman-Sidi" 1 => "O. Michielin" 2 => "C. Cervera" 3 => "C. Ribi" 4 => "J.M. Aguado" 5 => "M. Fernández-Ruiz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.cmi.2018.01.030" "Revista" => array:7 [ "tituloSerie" => "Clin Microbiol Infect" "fecha" => "2018" "volumen" => "24" "numero" => "Suppl. 2" "paginaInicial" => "S95" "paginaFinal" => "S107" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29427804" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0335" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "M.F. Doran" 1 => "C.S. Crowson" 2 => "G.R. Pond" 3 => "W.M. O’Fallon" 4 => "S.E. Gabriel" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2002" "volumen" => "46" "paginaInicial" => "2287" "paginaFinal" => "2293" ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0340" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "management of infections in rheumatic patients receiving biological therapies. The Portuguese Society of rheumatology recommendations" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Teixeira" 1 => "A.R. Fonseca" 2 => "G. Eugénio" 3 => "M. Rodrigues" 4 => "N. Khmelinskii" 5 => "S. Fernandes" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Acta Reumatol Port" "fecha" => "2016" "volumen" => "2016" "paginaInicial" => "287" "paginaFinal" => "304" ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0345" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.R. Curtis" 1 => "S. Yang" 2 => "N.M. Patkar" 3 => "L. Chen" 4 => "J.A. Singh" 5 => "G.W. Cannon" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Arthritis Care Res" "fecha" => "2014" "volumen" => "66" "paginaInicial" => "990" "paginaFinal" => "997" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0350" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Risk of hospitalization for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the record study of the Italian society for rheumatology" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "G. Carrara" 1 => "A. Bortoluzzi" 2 => "G. Sakellariou" 3 => "M. Govoni" 4 => "C.A. Scirè" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Clin Exp Rheumatol" "fecha" => "2019" "volumen" => "37" "paginaInicial" => "60" "paginaFinal" => "66" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30148440" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0355" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: a multicenter retrospective cohort study in Japan" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Mori" 1 => "T. Yoshitama" 2 => "T. Hidaka" 3 => "F. Sakai" 4 => "M. Hasegawa" 5 => "Y. Hashiba" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pone.0179179" "Revista" => array:5 [ "tituloSerie" => "PLOS ONE" "fecha" => "2017" "volumen" => "12" "paginaInicial" => "1" "paginaFinal" => "16" ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0360" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.A. Singh" 1 => "C. Cameron" 2 => "S. Noorbaloochi" 3 => "T. Cullis" 4 => "M. Tucker" 5 => "R. Christensen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(14)61704-9" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2015" "volumen" => "386" "paginaInicial" => "258" "paginaFinal" => "265" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25975452" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0365" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "S. Bonovas" 1 => "G. Fiorino" 2 => "M. Allocca" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.cgh.2016.04.039" "Revista" => array:6 [ "tituloSerie" => "Clin Gastroenterol Hepatol" "fecha" => "2016" "volumen" => "14" "paginaInicial" => "1385" "paginaFinal" => "1397" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27189910" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0370" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Askling" 1 => "C.M. Fored" 2 => "L. Brandt" 3 => "E. Baecklund" 4 => "L. Bertilsson" 5 => "N. Feltelius" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2006.062760" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2007" "volumen" => "66" "paginaInicial" => "1339" "paginaFinal" => "1344" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17261532" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0375" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.M. Fleischmann" 1 => "J. Schechtman" 2 => "R. Bennett" 3 => "M.L. Handel" 4 => "G.R. Burmester" 5 => "J. Tesser" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.10870" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2003" "volumen" => "48" "paginaInicial" => "927" "paginaFinal" => "934" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12687534" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0380" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A.A. Den Broeder" 1 => "E. De Jong" 2 => "M.J.A.M. Franssen" 3 => "M.E.C. Jeurissen" 4 => "M. Flendrie" 5 => "F.H.J. Van Den Hoogen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2004.033662" "Revista" => array:7 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2006" "volumen" => "65" "paginaInicial" => "760" "paginaFinal" => "762" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16269431" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0165178114003886" "estado" => "S300" "issn" => "01651781" ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0385" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Safety of extended treatment with anakinra in patients with rheumatoid arthritis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Fleischmann" 1 => "J. Tesser" 2 => "M.H. Schiff" 3 => "J. Schechtman" 4 => "G.R. Burmester" 5 => "R. Bennett" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2005.048371" "Revista" => array:7 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2006" "volumen" => "65" "paginaInicial" => "1006" "paginaFinal" => "1012" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16396977" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0165032714004492" "estado" => "S300" "issn" => "01650327" ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0390" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G.R. Burmester" 1 => "Y. Lin" 2 => "R. Patel" 3 => "J. Van Adelsberg" 4 => "E.K. Mangan" 5 => "N.M.H. Graham" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/annrheumdis-2016-210310" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2017" "volumen" => "76" "paginaInicial" => "840" "paginaFinal" => "847" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27856432" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0395" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Iking-Konert" 1 => "U. Von Hinüber" 2 => "C. Richter" 3 => "H. Schwenke" 4 => "I. Gürtler" 5 => "P. Kästner" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rheumatology (United Kingdom)" "fecha" => "2016" "volumen" => "55" "paginaInicial" => "624" "paginaFinal" => "635" ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0400" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Integrated safety in tocilizumab clinical trials" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "M.H. Schiff" 1 => "J.M. Kremer" 2 => "A. Jahreis" 3 => "E. Vernon" 4 => "J.D. Isaacs" 5 => "R.F. van Vollenhoven" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Arthritis Res Ther" "fecha" => "2011" "volumen" => "13" ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0405" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T. Koike" 1 => "M. Harigai" 2 => "S. Inokuma" 3 => "N. Ishiguro" 4 => "J. Ryu" 5 => "T. Takeuchi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3899/jrheum.130466" "Revista" => array:6 [ "tituloSerie" => "J Rheumatol" "fecha" => "2014" "volumen" => "41" "paginaInicial" => "15" "paginaFinal" => "23" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24187110" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0410" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P.C.M. Van De Kerkhof" 1 => "C.E.M. Griffiths" 2 => "K. Reich" 3 => "C.L. Leonardi" 4 => "A. Blauvelt" 5 => "T.F. Tsai" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2016.03.024" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2016" "volumen" => "75" "paginaInicial" => "83" "paginaFinal" => "98" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27180926" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0415" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Infections from 7 clinical trials of Ixekizumab an anti-interleukin-17A monoclonal antibody in patients with moderate-to-severe psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K.A. Papp" 1 => "H. Bachelez" 2 => "A. Blauvelt" 3 => "K.L. Winthrop" 4 => "R. Romiti" 5 => "M. Ohtsuki" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2017" "volumen" => "167" "paginaInicial" => "1537" "paginaFinal" => "1551" ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0420" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatology" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.E. Kalb" 1 => "D.F. Fiorentino" 2 => "M.G. Lebwohl" 3 => "J. Toole" 4 => "Y. Poulin" 5 => "A.D. Cohen" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "fecha" => "2015" "volumen" => "151" "paginaInicial" => "961" "paginaFinal" => "969" ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0425" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bevacizumab increases the risk of infections in cancer patients: a systematic review and pooled analysis of 41 randomized controlled trials" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "W.X. Qi" 1 => "S. Fu" 2 => "Q. Zhang" 3 => "X.M. Guo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.critrevonc.2015.02.007" "Revista" => array:6 [ "tituloSerie" => "Crit Rev Oncol Hematol" "fecha" => "2015" "volumen" => "94" "paginaInicial" => "323" "paginaFinal" => "336" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25749417" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0430" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effects and side effects of using sorafenib and sunitinib in the treatment of metastatic renal cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "C.R. Hansen" 1 => "D. Grimm" 2 => "J. Bauer" 3 => "M. Wehland" 4 => "N.E. Magnusson" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Int J Mol Sci" "fecha" => "2017" "volumen" => "18" "paginaInicial" => "E461" ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0435" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E.B. Garon" 1 => "T.E. Ciuleanu" 2 => "O. Arrieta" 3 => "K. Prabhash" 4 => "K.N. Syrigos" 5 => "T. Goksel" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(14)60845-X" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2014" "volumen" => "384" "paginaInicial" => "665" "paginaFinal" => "673" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24933332" "web" => "Medline" ] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0440" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D. Arnold" 1 => "C.S. Fuchs" 2 => "J. Tabernero" 3 => "A. Ohtsu" 4 => "A.X. Zhu" 5 => "E.B. Garon" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/annonc/mdx514" "Revista" => array:6 [ "tituloSerie" => "Ann Oncol" "fecha" => "2017" "volumen" => "28" "paginaInicial" => "2932" "paginaFinal" => "2942" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28950290" "web" => "Medline" ] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0445" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "T. Funakoshi" 1 => "M. Suzuki" 2 => "K. Tamura" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ctrv.2014.09.002" "Revista" => array:6 [ "tituloSerie" => "Cancer Treat Rev" "fecha" => "2014" "volumen" => "40" "paginaInicial" => "1221" "paginaFinal" => "1229" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25288497" "web" => "Medline" ] ] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0450" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "W.X. Qi" 1 => "S. Fu" 2 => "Q. Zhang" 3 => "X.M. Guo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s12916-014-0231-1" "Revista" => array:6 [ "tituloSerie" => "BMC Med" "fecha" => "2014" "volumen" => "12" "paginaInicial" => "1" "paginaFinal" => "12" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25539784" "web" => "Medline" ] ] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib0455" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Infection risk in breast cancer patients treated with trastuzumab: a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "T. Funakoshi" 1 => "M. Suzuki" 2 => "H.B. Muss" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Breast Cancer Res Treat" "fecha" => "2015" "volumen" => "149" "paginaInicial" => "321" "paginaFinal" => "330" ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib0460" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.C. Byrd" 1 => "R.R. Furman" 2 => "S.E. Coutre" 3 => "I.W. Flinn" 4 => "J.A. Burger" 5 => "K.A. Blum" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1215637" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2013" "volumen" => "369" "paginaInicial" => "32" "paginaFinal" => "42" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23782158" "web" => "Medline" ] ] ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib0465" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.L. Wang" 1 => "S. Rule" 2 => "P. Martin" 3 => "A. Goy" 4 => "R. Auer" 5 => "B.S. Kahl" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1306220" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2013" "volumen" => "369" "paginaInicial" => "507" "paginaFinal" => "516" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23782157" "web" => "Medline" ] ] ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib0470" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:5 [ 0 => "F. Cervantes" 1 => "A.M. Vannucchi" 2 => "J.-J. Kiladjian" 3 => "H.K. Al-Ali" 4 => "A. Sirulnik" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Blood" "fecha" => "2013" "volumen" => "122" "paginaInicial" => "4047" "paginaFinal" => "4053" ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib0475" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Attributable risk of infection to mTOR inhibitors everolimus and temsirolimus in the treatment of cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "C.A. Garcia" 1 => "S. Wu" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/07357907.2016.1242009" "Revista" => array:6 [ "tituloSerie" => "Cancer Invest" "fecha" => "2016" "volumen" => "34" "paginaInicial" => "521" "paginaFinal" => "530" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27791402" "web" => "Medline" ] ] ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib0480" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H. Kantarjian" 1 => "A. Stein" 2 => "N. Gökbuget" 3 => "A.K. Fielding" 4 => "A.C. Schuh" 5 => "J.-M. Ribera" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1609783" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2017" "volumen" => "376" "paginaInicial" => "836" "paginaFinal" => "847" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28249141" "web" => "Medline" ] ] ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib0485" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: results from 2 phase 2 studies" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H.M. Kantarjian" 1 => "A.S. Stein" 2 => "R.C. Bargou" 3 => "C. Grande Garcia" 4 => "R.A. Larson" 5 => "M. Stelljes" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/cncr.30031" "Revista" => array:7 [ "tituloSerie" => "Cancer" "fecha" => "2016" "volumen" => "122" "paginaInicial" => "2178" "paginaFinal" => "2185" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27143254" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0140673610619976" "estado" => "S300" "issn" => "01406736" ] ] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib0490" "etiqueta" => "41" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Complete hematologic and molecular response in adult patients with relapsed/refractory philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. Martinelli" 1 => "N. Boisel" 2 => "P. Chevalier" 3 => "Ottman o" 4 => "N. Gükbuget" 5 => "M.S. Topp" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2016.69.3531" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2017" "volumen" => "35" "paginaInicial" => "1795" "paginaFinal" => "1802" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28355115" "web" => "Medline" ] ] ] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib0495" "etiqueta" => "42" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Schiopu" 1 => "S. Chatterjee" 2 => "V. Hsu" 3 => "A. Flor" 4 => "D. Cimbora" 5 => "K. Patra" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s13075-016-1021-2" "Revista" => array:6 [ "tituloSerie" => "Arthritis Res Ther" "fecha" => "2016" "volumen" => "18" "paginaInicial" => "1" "paginaFinal" => "14" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26732314" "web" => "Medline" ] ] ] ] ] ] ] ] 42 => array:3 [ "identificador" => "bib0500" "etiqueta" => "43" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "S. Lanini" 1 => "A.C. Molloy" 2 => "P.E. Fine" 3 => "A.G. Prentice" 4 => "G. Ippolito" 5 => "C.C. Kibbler" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1741-7015-9-36" "Revista" => array:5 [ "tituloSerie" => "BMC Med" "fecha" => "2011" "volumen" => "9" "paginaInicial" => "36" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21481281" "web" => "Medline" ] ] ] ] ] ] ] ] 43 => array:3 [ "identificador" => "bib0505" "etiqueta" => "44" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Longterm safety of rituximab: Final report of the rheumatoid arthritis global clinical trial program over 11 years" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "R.F. Van Vollenhoven" 1 => "R.M. Fleischmann" 2 => "D.E. Furst" 3 => "S. Lacey" 4 => "P.B. Lehane" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3899/jrheum.150051" "Revista" => array:6 [ "tituloSerie" => "J Rheumatol" "fecha" => "2015" "volumen" => "42" "paginaInicial" => "1761" "paginaFinal" => "1766" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26276965" "web" => "Medline" ] ] ] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib0510" "etiqueta" => "45" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Infections in non-splenectomized persistent or chronic primary immune thrombocytopenia adults: risk factors and vaccination effect" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "G. Moulis" 1 => "M. Lapeyre-Mestre" 2 => "A. Palmaro" 3 => "L. Sailler" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/jth.13622" "Revista" => array:6 [ "tituloSerie" => "J Thromb Haemost" "fecha" => "2016" "volumen" => "15" "paginaInicial" => "785" "paginaFinal" => "791" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28078756" "web" => "Medline" ] ] ] ] ] ] ] ] 45 => array:3 [ "identificador" => "bib0515" "etiqueta" => "46" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "K.A. Thursky" 1 => "L.J. Worth" 2 => "J.F. Seymour" 3 => "H. Miles Prince" 4 => "M.A. Slavin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2141.2005.05789.x" "Revista" => array:6 [ "tituloSerie" => "Br J Haematol" "fecha" => "2006" "volumen" => "132" "paginaInicial" => "3" "paginaFinal" => "12" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16371014" "web" => "Medline" ] ] ] ] ] ] ] ] 46 => array:3 [ "identificador" => "bib0520" "etiqueta" => "47" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.D. Wolchok" 1 => "B. Neyns" 2 => "G. Linette" 3 => "S. Negrier" 4 => "J. Lutzky" 5 => "L. Thomas" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S1470-2045(09)70334-1" "Revista" => array:6 [ "tituloSerie" => "Lancet Oncol" "fecha" => "2010" "volumen" => "11" "paginaInicial" => "155" "paginaFinal" => "164" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20004617" "web" => "Medline" ] ] ] ] ] ] ] ] 47 => array:3 [ "identificador" => "bib0525" "etiqueta" => "48" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The safety of anti PD-1 therapeutics for the treatment of melanoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "E. Ramelyte" 1 => "S.A. Schindler" 2 => "R. Dummer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/14740338.2016.1248402" "Revista" => array:6 [ "tituloSerie" => "Expert Opin Drug Saf" "fecha" => "2017" "volumen" => "16" "paginaInicial" => "41" "paginaFinal" => "53" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27737598" "web" => "Medline" ] ] ] ] ] ] ] ] 48 => array:3 [ "identificador" => "bib0530" "etiqueta" => "49" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "safety and activity of anti-PD-L1 antibody in patients with advanced cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.R. Brahmer" 1 => "S.S. Tykodi" 2 => "L.Q.M. Chow" 3 => "W.-J. Hwu" 4 => "S.L. Topalian" 5 => "P. Hwu" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1200694" "Revista" => array:7 [ "tituloSerie" => "N Engl J Med" "fecha" => "2012" "volumen" => "366" "paginaInicial" => "2455" "paginaFinal" => "2465" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22658128" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0165178116304504" "estado" => "S300" "issn" => "01651781" ] ] ] ] ] ] ] 49 => array:3 [ "identificador" => "bib0535" "etiqueta" => "50" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Fehrenbacher" 1 => "A. Spira" 2 => "M. Ballinger" 3 => "M. Kowanetz" 4 => "J. Vansteenkiste" 5 => "J. Mazieres" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(16)00587-0" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2016" "volumen" => "387" "paginaInicial" => "1837" "paginaFinal" => "1846" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26970723" "web" => "Medline" ] ] ] ] ] ] ] ] 50 => array:3 [ "identificador" => "bib0540" "etiqueta" => "51" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Robert" 1 => "A. Ribas" 2 => "J.D. Wolchok" 3 => "F.S. Hodi" 4 => "O. Hamid" 5 => "R. Kefford" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(14)60958-2" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2014" "volumen" => "384" "paginaInicial" => "1109" "paginaFinal" => "1117" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25034862" "web" => "Medline" ] ] ] ] ] ] ] ] 51 => array:3 [ "identificador" => "bib0545" "etiqueta" => "52" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "W.A. Bye" 1 => "V. Jairath" 2 => "S.P.L. Travis" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/apt.14075" "Revista" => array:7 [ "tituloSerie" => "Aliment Pharmacol Ther" "fecha" => "2017" "volumen" => "46" "paginaInicial" => "3" "paginaFinal" => "15" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28449273" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1525505016000755" "estado" => "S300" "issn" => "15255050" ] ] ] ] ] ] ] 52 => array:3 [ "identificador" => "bib0550" "etiqueta" => "53" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): and randomised, phase 3, open-label, multicentre study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.A. Dimopoulos" 1 => "P. Moreau" 2 => "A. Palumbo" 3 => "D. Joshua" 4 => "L. Pour" 5 => "R. Hájek" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S1470-2045(15)00464-7" "Revista" => array:6 [ "tituloSerie" => "Lancet Oncol" "fecha" => "2016" "volumen" => "17" "paginaInicial" => "27" "paginaFinal" => "38" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26671818" "web" => "Medline" ] ] ] ] ] ] ] ] 53 => array:3 [ "identificador" => "bib0555" "etiqueta" => "54" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "K.J. Maddocks" 1 => "A.S. Ruppert" 2 => "G. Lozanski" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jamaoncol.2014.218" "Revista" => array:6 [ "tituloSerie" => "JAMA Oncol" "fecha" => "2015" "volumen" => "1" "paginaInicial" => "80" "paginaFinal" => "87" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26182309" "web" => "Medline" ] ] ] ] ] ] ] ] 54 => array:3 [ "identificador" => "bib0560" "etiqueta" => "55" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Asymptomatic bacteriuria in women with autoimmune rheumatic disease: prevalence, risk factors, and clinical significance" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.P. Georgiadou" 1 => "M.N. Gamaletsou" 2 => "I. Mpanaka" 3 => "A. Vlachou" 4 => "A.V. Goules" 5 => "D.C. Ziogas" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2015" "volumen" => "60" "paginaInicial" => "868" "paginaFinal" => "874" ] ] ] ] ] ] 55 => array:3 [ "identificador" => "bib0565" "etiqueta" => "56" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Maternal and neonatal consequences of treated and untreated asymptomatic bacteriuria in pregnancy: a prospective cohort study with an embedded randomised controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B.M. Kazemier" 1 => "F.N. Koningstein" 2 => "C. Schneeberger" 3 => "A. Ott" 4 => "P.M. Bossuyt" 5 => "E. de Miranda" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S1473-3099(15)00070-5" "Revista" => array:6 [ "tituloSerie" => "Lancet Infect Dis" "fecha" => "2015" "volumen" => "15" "paginaInicial" => "1324" "paginaFinal" => "1333" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26255208" "web" => "Medline" ] ] ] ] ] ] ] ] 56 => array:3 [ "identificador" => "bib0570" "etiqueta" => "57" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Should asymptomatic bacteriuria be systematically treated in kidney transplant recipients? Results from a randomized controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Origüen" 1 => "F. López-Medrano" 2 => "M. Fernández-Ruiz" 3 => "N. Polanco" 4 => "E. Gutiérrez" 5 => "E. González" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/ajt.13829" "Revista" => array:6 [ "tituloSerie" => "Am J Transplant" "fecha" => "2016" "volumen" => "16" "paginaInicial" => "2943" "paginaFinal" => "2953" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27088545" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/2529993X/0000004000000005/v1_202205140740/S2529993X22000879/v1_202205140740/en/main.assets" "Apartado" => array:4 [ "identificador" => "63563" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Review article" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/2529993X/0000004000000005/v1_202205140740/S2529993X22000879/v1_202205140740/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529993X22000879?idApp=UINPBA00004N"]

Statistics

Review article

Is there a real risk of bacterial infection in patients receiving targeted and biological therapies?

¿Existe un riesgo real de infección bacteriana en pacientes que reciben terapias biológicas?

Ivan Noreñaa,

Corresponding author

ivan.norena@lrz.uni-muenchen.de

Corresponding author.

, Mario Fernández-Ruizb, José María Aguadob,c

a Teaching and Training Unit, Division of Infectious Diseases and Tropical Medicine, LMU University Hospital Munich, Munich, Germany

b Unit of Infectious Diseases, Hospital Universitario “12 de Octubre”, Instituto de Investigación Sanitaria Hospital “12 de Octubre” (imas12), Madrid, Spain

c School of Medicine, Universidad Complutense. Madrid, Spain

Read

546

Times
was read the article

Total PDF

460

Total HTML

Share statistics

 array:23 [
  "pii" => "S2529993X22000879"
  "issn" => "2529993X"
  "doi" => "10.1016/j.eimce.2020.10.014"
  "estado" => "S300"
  "fechaPublicacion" => "2022-05-01"
  "aid" => "2328"
  "copyright" => "Sociedad Espa&#241;ola de Enfermedades Infecciosas y Microbiolog&#237;a Cl&#237;nica"
  "copyrightAnyo" => "2020"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "rev"
  "cita" => "Enferm Infecc Microbiol Clin. 2022;40:266-72"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:1 [
    "total" => 0
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S2529993X22000399"
    "issn" => "2529993X"
    "doi" => "10.1016/j.eimce.2022.02.010"
    "estado" => "S300"
    "fechaPublicacion" => "2022-05-01"
    "aid" => "2461"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "crp"
    "cita" => "Enferm Infecc Microbiol Clin. 2022;40:273-4"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Diagnosis at first sight</span>"
      "titulo" => "Unexpected cause of ischemic lesions in an immunocompetent patient"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "273"
          "paginaFinal" => "274"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Causa inesperada de lesiones isqu&#233;micas en paciente inmunocompetente"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig0005"
          "etiqueta" => "Fig&#46; 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 984
              "Ancho" => 905
              "Tamanyo" => 66766
            ]
          ]
          "detalles" => array:1 [
            0 => array:3 [
              "identificador" => "at0005"
              "detalle" => "Fig&#46; "
              "rol" => "short"
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">T1-weighted transverse slice showing significant inflammatory component of the right sinus and orbital structures with slight protrusion of the eyeball&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Antonio Bustos-Merlo, Antonio Rosales-Castillo, Virginia Sotorr&#237;o Simo"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "Antonio"
              "apellidos" => "Bustos-Merlo"
            ]
            1 => array:2 [
              "nombre" => "Antonio"
              "apellidos" => "Rosales-Castillo"
            ]
            2 => array:2 [
              "nombre" => "Virginia"
              "apellidos" => "Sotorr&#237;o Simo"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0213005X21002214"
        "doi" => "10.1016/j.eimc.2021.06.020"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X21002214?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529993X22000399?idApp=UINPBA00004N"
    "url" => "/2529993X/0000004000000005/v1_202205140740/S2529993X22000399/v1_202205140740/en/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S2529993X22001022"
    "issn" => "2529993X"
    "doi" => "10.1016/j.eimce.2021.05.015"
    "estado" => "S300"
    "fechaPublicacion" => "2022-05-01"
    "aid" => "2435"
    "copyright" => "Sociedad Espa&#241;ola de Enfermedades Infecciosas y Microbiolog&#237;a Cl&#237;nica"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "fla"
    "cita" => "Enferm Infecc Microbiol Clin. 2022;40:262-5"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Brief report</span>"
      "titulo" => "First importations of SARS-CoV-2 P&#46;1 and P&#46;2 variants from Brazil to Spain and early community transmission"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "262"
          "paginaFinal" => "265"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Primeras importaciones de las variantes SARS-CoV-2 P&#46;1 y P&#46;2 de Brasil a Madrid y transmisi&#243;n comunitaria"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Fig&#46; 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1967
              "Ancho" => 3500
              "Tamanyo" => 824748
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Phylogenetic relationship of SARS-CoV-2 based on the alignment of all P&#46;1 &#40;panel A&#41; and P&#46;2 sequences &#40;panel B&#41; from Brazil &#40;completed &#40;&#62;29<span class="elsevierStyleHsp" style=""></span>000<span class="elsevierStyleHsp" style=""></span>bp&#41; with high coverage &#40;&#60;1&#37; Ns&#41;&#41; deposited in GISAID up to March 15&#44; 2021 &#40;714 and 477 samples respectively&#41;&#46; Maximum likelihood unrooted tree displaying the genetic distance between all samples collected and the new presented in this study&#44; colored by their lineage&#44; was performed by a multi-alignment with mafft and IQ-TREE GTR<span class="elsevierStyleHsp" style=""></span>&#43;F<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>R2 mode with 1000 bootstrap replications&#46; Reference for our sequences in GIDAID are&#58; EPI&#95;ISL&#95;985404 &#40;P&#46;1&#41;&#44; EPI&#95;ISL&#95;985408 &#40;P&#46;2&#41;&#44; EPI&#95;ISL&#95;985409 &#40;P&#46;2&#41;&#44; EPI&#95;ISL&#95;1233413 &#40;P&#46;2&#41;&#44; EPI&#95;ISL&#95;1381872 &#40;P&#46;1&#41;&#44; EPI&#95;ISL&#95;1477061 &#40;P&#46;1&#41; and EPI&#95;ISL&#95;1647839 &#40;P&#46;2&#41;&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Pedro J&#46; Sola Campoy, Sergio Buenestado-Serrano, Laura P&#233;rez-Lago, Cristina Rodriguez-Grande, Pilar Catal&#225;n, Cristina Andr&#233;s-Zayas, Luis Alcal&#225;, Carmen Losada, Carla Rico-Luna, Patricia Mu&#241;oz, Dar&#237;o Garc&#237;a de Viedma"
          "autores" => array:12 [
            0 => array:2 [
              "nombre" => "Pedro J&#46;"
              "apellidos" => "Sola Campoy"
            ]
            1 => array:2 [
              "nombre" => "Sergio"
              "apellidos" => "Buenestado-Serrano"
            ]
            2 => array:2 [
              "nombre" => "Laura"
              "apellidos" => "P&#233;rez-Lago"
            ]
            3 => array:2 [
              "nombre" => "Cristina"
              "apellidos" => "Rodriguez-Grande"
            ]
            4 => array:2 [
              "nombre" => "Pilar"
              "apellidos" => "Catal&#225;n"
            ]
            5 => array:2 [
              "nombre" => "Cristina"
              "apellidos" => "Andr&#233;s-Zayas"
            ]
            6 => array:2 [
              "nombre" => "Luis"
              "apellidos" => "Alcal&#225;"
            ]
            7 => array:2 [
              "nombre" => "Carmen"
              "apellidos" => "Losada"
            ]
            8 => array:2 [
              "nombre" => "Carla"
              "apellidos" => "Rico-Luna"
            ]
            9 => array:2 [
              "nombre" => "Patricia"
              "apellidos" => "Mu&#241;oz"
            ]
            10 => array:2 [
              "nombre" => "Dar&#237;o"
              "apellidos" => "Garc&#237;a de Viedma"
            ]
            11 => array:1 [
              "colaborador" => "on behalf of the Gregorio Mara&#241;&#243;n Microbiology-ID COVID 19 Study Group"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529993X22001022?idApp=UINPBA00004N"
    "url" => "/2529993X/0000004000000005/v1_202205140740/S2529993X22001022/v1_202205140740/en/main.assets"
  ]
  "en" => array:18 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Review article</span>"
    "titulo" => "Is there a real risk of bacterial infection in patients receiving targeted and biological therapies&#63;"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "266"
        "paginaFinal" => "272"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Ivan Nore&#241;a, Mario Fern&#225;ndez-Ruiz, Jos&#233; Mar&#237;a Aguado"
        "autores" => array:3 [
          0 => array:4 [
            "nombre" => "Ivan"
            "apellidos" => "Nore&#241;a"
            "email" => array:1 [
              0 => "ivan.norena@lrz.uni-muenchen.de"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Mario"
            "apellidos" => "Fern&#225;ndez-Ruiz"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Jos&#233; Mar&#237;a"
            "apellidos" => "Aguado"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:3 [
          0 => array:3 [
            "entidad" => "Teaching and Training Unit&#44; Division of Infectious Diseases and Tropical Medicine&#44; LMU University Hospital Munich&#44; Munich&#44; Germany"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Unit of Infectious Diseases&#44; Hospital Universitario &#8220;12 de Octubre&#8221;&#44; Instituto de Investigaci&#243;n Sanitaria Hospital &#8220;12 de Octubre&#8221; &#40;imas12&#41;&#44; Madrid&#44; Spain"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "School of Medicine&#44; Universidad Complutense&#46; Madrid&#44; Spain"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "&#191;Existe un riesgo real de infecci&#243;n bacteriana en pacientes que reciben terapias biol&#243;gicas&#63;"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Over the last twenty years&#44; the introduction of targeted and biological therapies has revolutionized the treatment of solid cancer and hematological and inflammatory diseases&#46; The increasing experience with these agents has allowed to estimate the associated risk of developing opportunistic infections&#44; such as invasive aspergillosis&#44; shingles or <span class="elsevierStyleItalic">Pneumocystis jirovecii</span> pneumonia&#46;<a class="elsevierStyleCrossRef" href="#bib0290"><span class="elsevierStyleSup">1</span></a> Targeted and biologic therapies produce different blockages in the immune pathways involved in both the innate and adaptive responses related to the host-bacteria interaction&#44; which could increase the susceptibility to severe bacterial infections&#46;<a class="elsevierStyleCrossRef" href="#bib0295"><span class="elsevierStyleSup">2</span></a> Nevertheless&#44; this specific risk has not yet been completely elucidated&#44; and recommendations are mainly based on expert opinions&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">The present review summarizes the information concerning the risk and management of bacterial infection in patients receiving targeted and biological therapies&#46; We performed a computer-based MEDLINE &#40;National Library of Medicine&#44; Bethesda&#44; MD&#41; search with no temporal or language restrictions&#44; using the MeSH terms appropriate for each agent &#40;always including &#8220;infection&#8221; or &#8220;infectious complications&#8221;&#41; to capture the literature pertaining to the subject&#46; Particular attention was given to the safety data reported across pivotal randomized controlled trials &#40;RCTs&#41; and relevant post-marketing surveillance studies&#46; The references of selected articles were also examined for additional related references&#46; We have also collected information from the recommendations issued by the European Society of Clinical Microbiology and Infectious Diseases &#40;ESCMID&#41; Study Group for Infections in Compromised Hosts &#40;ESGICH&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0295"><span class="elsevierStyleSup">2&#8211;9</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">Which factors related to bacterial infections have to be considered before the initiation of targeted and biological therapies&#63;</p><p id="par0020" class="elsevierStylePara elsevierViewall">First&#44; we should consider that many autoimmune and inflammatory diseases intrinsically confer an increased baseline susceptibility to bacterial pathogens&#46; Therefore&#44; those patients with severe underlying conditions could be at additional risk once the therapy is initiated&#46;<a class="elsevierStyleCrossRef" href="#bib0335"><span class="elsevierStyleSup">10</span></a><a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a> depicts some risk factors that could increase concomitantly the risk of bacterial infection in patients with rheumatic diseases receiving targeted therapies&#46;<a class="elsevierStyleCrossRefs" href="#bib0340"><span class="elsevierStyleSup">11&#44;12</span></a> The presence of previous debilitating chronic disorders &#40;e&#46;g&#46; chronic obstructive pulmonary disease&#44; interstitial lung disease or chronic kidney disease&#41;&#44;<a class="elsevierStyleCrossRefs" href="#bib0340"><span class="elsevierStyleSup">11&#44;12</span></a> the previous occurrence of serious infections&#44; and high cumulative doses of corticosteroids also act as contributing factors&#46; Despite the paucity of supporting data&#44; numerous guidelines recommend not to initiate any biological therapy in patients with a concomitant severe active infection &#40;which is usually defined as that requiring intravenous treatment or hospitalization&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0340"><span class="elsevierStyleSup">11</span></a></p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">What is the risk of developing a bacterial infection with the different targeted and biological agents&#63;</span><p id="par0025" class="elsevierStylePara elsevierViewall">We have reviewed the existing experience by classifying the biological agents into six large categories according to their intimate mechanism of action &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Soluble immune effector molecules and pro-inflammatory cytokines&#58; anti-TNF-&#945; agents</span><p id="par0030" class="elsevierStylePara elsevierViewall">Most relevant data related to the specific risk of bacterial infection in patients receiving targeted and biological agents are derived from the experience with the therapeutic blockade of tumor necrosis factor &#40;TNF&#41;-&#945; in rheumatoid arthritis &#40;RA&#41; and inflammatory bowel disease &#40;IBD&#41;&#46; This theoretical background is often extensible to other indications with a more limited clinical experience&#46; Curtis et al&#46; analyzed the incidence of common bacterial infections with anti-TNF-&#945; agents &#40;abatacept&#44; rituximab&#44; infliximab&#44; etanercept and adalimumab&#41; in a large cohort &#40;<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>3111&#41; of RA patients from the US Veterans Health Administration between 1998 and 2011&#44; reporting high rates for pneumonia &#40;37&#37;&#41;&#44; cellulitis and soft tissue infection &#40;22&#37;&#41;&#44; and urinary tract infection &#40;9&#37;&#41;&#46; In this study&#44; the use of abatacept was associated with a higher rate of bacterial infection-related hospitalization&#44; although the multivariate analysis revealed no differences across different agents&#46; The risk of infection was greater among patients receiving corticosteroids &#40;daily prednisone dose<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>7&#46;5<span class="elsevierStyleHsp" style=""></span>mg or equivalent&#41; and for those in the highest quartile of C-reactive protein levels and erythrocyte sedimentation rate &#40;as compared to the lowest quartile&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0345"><span class="elsevierStyleSup">12</span></a> More recently&#44; Carrara et al&#46; estimated in an Italian cohort of RA patients &#40;<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>4656&#41; incidence rates for pneumonia&#44; bloodstream infection&#44; cellulitis and septic arthritis of 2&#46;95&#44; 2&#46;51&#44; 1&#46;30 and 1&#46;06 episodes per 1000 patient-years&#44; respectively&#46; Abatacept seemed to be protective for severe infection-related hospitalization as compared to etanercept&#44; while the use of other agents was not shown to increase the infection risk compared with this anti-TNF-&#945; agent&#46; Additional risk factors included the occurrence of severe infection within the previous year and high corticosteroid doses&#46;<a class="elsevierStyleCrossRef" href="#bib0350"><span class="elsevierStyleSup">13</span></a> A Japanese cohort found a higher incidence of pulmonary infection among patients receiving adalimumab&#44; with no differences between different biological agents in the overall risk of infection&#46; These authors also found a significantly increased risk related to older age&#44; RA severity&#44; low body mass index&#44; and presence of chronic comorbidities such as diabetes&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">14</span></a> A network meta-analysis for severe infection in RA patients found that standard- &#40;odds ratio &#91;OR&#93;&#58; 1&#46;31&#59; 95&#37; confidence interval &#91;CI&#93;&#58; 1&#46;09&#8211;1&#46;58&#41; and high-dose &#40;OR&#58; 1&#46;90&#59; 95&#37; CI&#58; 1&#46;50&#8211;2&#46;39&#41; therapy with biological agents were both associated with a higher risk for severe infection&#44; although such difference was not significant for methotrexate &#40;MTX&#41; <span class="elsevierStyleItalic">na&#239;ve</span> and anti-TNF-&#945; experienced patients&#46;<a class="elsevierStyleCrossRef" href="#bib0360"><span class="elsevierStyleSup">15</span></a> In a meta-analysis of IBD patients receiving different anti-TNF-&#945; agents and other therapies &#40;vedolizumab or natalizumab&#41;&#44; the incidence of serious infection was not significantly increased as compared to placebo &#40;OR&#58; 0&#46;89&#59; 95&#37; CI&#58; 0&#46;71&#8211;1&#46;12&#41;&#46; Nevertheless&#44; the overall risk of infection was higher in those patients on biologic agents &#40;OR&#58; 1&#46;19&#59; 95&#37; CI&#58; 1&#46;10&#8211;1&#46;29&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0365"><span class="elsevierStyleSup">16</span></a> In summary&#44; there is limited evidence suggesting an increase in the risk of bacterial infection with the use of anti-TNF-&#945; agents&#46; Of note&#44; infections occur most frequently within the first year since the initiation of therapy&#46;<a class="elsevierStyleCrossRef" href="#bib0370"><span class="elsevierStyleSup">17</span></a></p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Agents targeting interleukins&#44; immunoglobulins and complement factors</span><p id="par0035" class="elsevierStylePara elsevierViewall">Therapy with interleukin &#40;IL&#41;-1-targeted agents has been shown to be associated with a moderate increase in the risk of bacterial infection&#44; mainly in form of respiratory&#44; urinary tract and skin and skin structure infections&#46;<a class="elsevierStyleCrossRefs" href="#bib0375"><span class="elsevierStyleSup">18&#44;19</span></a> The reported incidence of serious infection is 5&#46;4 episodes per 100 patient-years and seems to be increased among older patients with previous chronic diseases&#46;<a class="elsevierStyleCrossRef" href="#bib0385"><span class="elsevierStyleSup">20</span></a> IL-6&#47;IL-6R-targeted agents are associated with an increase in the risk of bacterial infection comparable to that observed with anti-TNF-&#945; therapies&#44; with pneumonia&#44; urinary tract infection and cellulitis as the most commonly reported events&#46;<a class="elsevierStyleCrossRefs" href="#bib0390"><span class="elsevierStyleSup">21&#44;22</span></a> The pooled estimate for serious infection in phase 3 and extension RCTs is 4&#46;9 episodes per 100 patient-years&#44;<a class="elsevierStyleCrossRef" href="#bib0400"><span class="elsevierStyleSup">23</span></a> with higher rates in population-based studies &#40;9&#46;0 episodes per 100 patient-years&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0405"><span class="elsevierStyleSup">24</span></a> It is important to note that most of the available experience with IL-6 blockade is restricted to tocilizumab&#44; with limited data for sarilumab or siltuximab&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">Phase 2 and 3 RCTs evaluating the use of IL-17-targeted agents in patients with psoriasis&#44; ankylosing spondylitis and psoriatic arthritis showed a minor increase in the risk of bacterial infection &#40;2&#46;4 episodes of serious infection per 100 patient-years&#41;&#44; usually mild to moderate in severity&#46; Upper respiratory and urinary tract infections were the most common syndromes&#44; whereas cellulitis was the predominant serious infection&#46;<a class="elsevierStyleCrossRefs" href="#bib0410"><span class="elsevierStyleSup">25&#44;26</span></a> IL-12&#47;23-targeted agents have not been associated with a significant increase in the risk of bacterial infection&#46;<a class="elsevierStyleCrossRef" href="#bib0420"><span class="elsevierStyleSup">27</span></a></p><p id="par0045" class="elsevierStylePara elsevierViewall">Eculizumab&#44; a humanized monoclonal antibody targeting and preventing cleavage of the terminal complement component C5&#44; notably predisposes to infections due to <span class="elsevierStyleItalic">Neisseria</span> spp&#46;&#44; with a 10&#44;000-fold increased risk for meningococcal infection&#46; In addition&#44; this agent has been associated with a significant increase in the risk of respiratory tract infection as compared to placebo&#46;<a class="elsevierStyleCrossRef" href="#bib0305"><span class="elsevierStyleSup">4</span></a></p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Cell-surface receptors and associated signaling pathways</span><p id="par0050" class="elsevierStylePara elsevierViewall">A large meta-analysis pooling data from 41 RCTs and more than 30&#44;000 patients with various cancer types &#40;mostly colorectal carcinoma&#41; that received vascular endothelial growth factor &#40;VEGF&#41;-targeted agents<a class="elsevierStyleCrossRef" href="#bib0425"><span class="elsevierStyleSup">28</span></a> concluded that the use of bevacizumab significantly increased the incidence of infection of any grade &#40;relative risk &#91;RR&#93;&#58; 1&#46;45&#59; 95&#37; CI&#58; 1&#46;27&#8211;1&#46;66&#41; and serious infection &#40;RR&#58; 1&#46;59&#59; 95&#37; CI&#58; 1&#46;42&#8211;1&#46;79&#41;&#46; In this meta-analysis&#44; the infection risk associated to bevacizumab seemed to be mostly linked to the occurrence of febrile neutropenia&#44; fistulae or abscesses&#44; and pneumonia&#44; but not sepsis or colitis&#46;<a class="elsevierStyleCrossRef" href="#bib0425"><span class="elsevierStyleSup">28</span></a></p><p id="par0055" class="elsevierStylePara elsevierViewall">Therapy with VEGF tyrosine kinase inhibitors does not increase the risk of infection&#46;<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">29</span></a> The use of anti-VEGFR2 monoclonal antibodies &#40;ramucirumab&#41; is likely associated with a risk increase similar to that observed for VEGF-targeted agents&#44; including the role of drug-induced neutropenia and gastrointestinal perforation as contributing factors&#46;<a class="elsevierStyleCrossRefs" href="#bib0435"><span class="elsevierStyleSup">30&#44;31</span></a></p><p id="par0060" class="elsevierStylePara elsevierViewall">The use of epidermal growth factor receptor &#40;EGFR&#41;-targeted agents is associated with a meaningful increase in the risk of infection&#44; mainly as a result of neutropenia and secondary infection in cases of severe papulopustular rash&#44; with <span class="elsevierStyleItalic">Staphylococcus aureus</span> as a remarkable causative microorganism in skin and skin structure infections&#46;<a class="elsevierStyleCrossRefs" href="#bib0445"><span class="elsevierStyleSup">32&#44;33</span></a></p><p id="par0065" class="elsevierStylePara elsevierViewall">Therapy with monoclonal antibodies targeting the human epidermal growth factor receptor 2 &#40;ErbB2&#47;HER2&#41; might be associated with a minor increase in the risk of infection&#46; However&#44; the biologic rationale and clinical evidence supporting this association are weak&#46;<a class="elsevierStyleCrossRef" href="#bib0455"><span class="elsevierStyleSup">34</span></a> Finally&#44; ErbB receptor tyrosine kinase-targeted agents &#40;including either selective EGFR&#47;HER1 and&#47;or ErbB2&#47;HER2 inhibitors or pan-ErbB inhibitors&#41; does not meaningfully increase the rate of bacterial infection&#46;<a class="elsevierStyleCrossRef" href="#bib0310"><span class="elsevierStyleSup">5</span></a></p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Intracellular signaling pathways &#40;tyrosine kinase and mTOR inhibitors&#41;</span><p id="par0070" class="elsevierStylePara elsevierViewall">With some exceptions&#44; this family of biologic agents does not show a significant increase in the susceptibility to bacterial pathogens&#46;<a class="elsevierStyleCrossRef" href="#bib0315"><span class="elsevierStyleSup">6</span></a> Ibrutinib &#40;a Bruton&#39;s tyrosine kinase &#91;BTK&#93; inhibitor&#41; exhibited a modest increase in the risk of bacterial infection&#46; Pneumonia is observed mainly in the presence of neutropenia&#44; whereas about 10&#37; of patients developed urinary tract infections&#46;<a class="elsevierStyleCrossRefs" href="#bib0460"><span class="elsevierStyleSup">35&#44;36</span></a> The risk is influenced by other factors like additional immunosuppressive drugs or previous immune disorders related to the underlying B-cell malignancies&#46;</p><p id="par0075" class="elsevierStylePara elsevierViewall">Janus kinase &#40;JAK&#41; inhibitors are associated with a considerable increase in the risk of infection&#46; Indeed&#44; urinary tract infection&#44; pneumonia&#44; and septic shock were described for patients on ruxolitinib &#40;a potent oral JAK1&#47;JAK2 inhibitor&#41; in rates of 24&#46;6&#37;&#44; 13&#46;1&#37; and 7&#46;9&#37;&#44; respectively&#44; in one pivotal RCT for the treatment of myelofibrosis&#46; Surprisingly&#44; the long-term follow-up revealed a decrease in the incidence of infection&#44; presumably resulting from the stabilization of the underlying disease with resolution of cytopenias&#46;<a class="elsevierStyleCrossRef" href="#bib0470"><span class="elsevierStyleSup">37</span></a></p><p id="par0080" class="elsevierStylePara elsevierViewall">A meta-analysis evaluating the use of mammalian target of rapamycin &#40;mTOR&#41; inhibitors in 4&#44;097 cancer patients from 12 RCTs &#40;8 with everolimus and 3 with temsirolimus&#41; reported an increased risk of infection &#40;overall incidence of all-grade infection of 25&#46;0&#37;&#59; 95&#37; CI&#58; 16&#46;7&#8211;35&#46;9&#37;&#41;&#44; including fatal outcomes due to sepsis and pneumonia&#46; Sub-group analysis revealed heterogeneity across different tumor types&#44; with lower risks for patients with giant cell astrocytoma&#44; breast cancer and angiomyolipoma&#44; and higher risks for those with renal cell carcinoma&#44; lymphomas or neuroendocrine tumors&#46;<a class="elsevierStyleCrossRef" href="#bib0475"><span class="elsevierStyleSup">38</span></a> The variations in dose regimens are relevant in explaining these findings as compared to the more favorable safety profile observed among solid organ transplant recipients&#46;<a class="elsevierStyleCrossRef" href="#bib0315"><span class="elsevierStyleSup">6</span></a></p><p id="par0085" class="elsevierStylePara elsevierViewall">BCR-ABL tyrosine kinase inhibitors&#44; BRAF&#47;MEK kinase inhibitors&#44; and PI3K inhibitors do not seem to increase the risk of serious bacterial infection&#44; whereas limited information is still available for BCL-2 inhibitors&#46;<a class="elsevierStyleCrossRef" href="#bib0315"><span class="elsevierStyleSup">6</span></a></p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Agents targeting lymphoid or myeloid cells surface antigens</span><p id="par0090" class="elsevierStylePara elsevierViewall">In pivotal RCTs&#44; mostly limited to blinatumomab&#44; therapy with CD19-targeted agents does not show a significant increase in the risk of bacterial infection compared with conventional chemotherapy&#44; with overall rates comparable to those expected in patients undergoing treatment for relapsed or refractory acute lymphoblastic leukemia&#46;<a class="elsevierStyleCrossRef" href="#bib0480"><span class="elsevierStyleSup">39</span></a> Of note&#44; the need for continuous intravenous infusion for 4 weeks in the blinatumomab regimen explains the elevated rate of catheter-associated bloodstream infection in the RCTs evaluating this first-in-class bispecific T-cell engager&#44; with rates ranging from 2&#46;2&#37; to 11&#37;&#46;<a class="elsevierStyleCrossRefs" href="#bib0485"><span class="elsevierStyleSup">40&#44;41</span></a> Careful management of intravenous lines is therefore warranted to minimize this risk&#46; Clinicians caring for patients receiving such therapy should be also aware of the associated risk of hypogammaglobulinemia &#40;HGG&#41;&#44; which is associated with a well-established increased susceptibility to encapsulated bacteria such as <span class="elsevierStyleItalic">Streptococcus pneumoniae</span>&#46;<a class="elsevierStyleCrossRef" href="#bib0495"><span class="elsevierStyleSup">42</span></a></p><p id="par0095" class="elsevierStylePara elsevierViewall">Infection prevails as the most common non-hematological adverse effects of anti-CD20 monoclonal antibodies&#44; including severe respiratory tract infection&#46; Separate meta-analysis in lymphoma and RA do not show a significant increase in the risk of bacterial infection&#46;<a class="elsevierStyleCrossRefs" href="#bib0500"><span class="elsevierStyleSup">43&#44;44</span></a> Nevertheless&#44; in a French cohort of patients with immune thrombocytopenia&#44; the incidence of serious bacterial infections was 6&#46;3 episodes per 100 patient-years&#44; and as high as 100&#46;5 episodes per 100 patient-years for non-serious infections&#46; Pneumonia was the most frequently reported syndrome &#40;42&#46;8&#37;&#41;&#44; with gastrointestinal and urinary tract infections as other common infections&#46;<a class="elsevierStyleCrossRef" href="#bib0510"><span class="elsevierStyleSup">45</span></a> Second- and third-generation anti-CD20 monoclonal antibodies could also increase the risk of bacterial infection&#44; although this risk is determined by the presence of concomitant comorbidities&#44; previous and concomitant immunosuppressive therapies&#44; and the long-term occurrence of sever HGG&#46;<a class="elsevierStyleCrossRef" href="#bib0320"><span class="elsevierStyleSup">7</span></a></p><p id="par0100" class="elsevierStylePara elsevierViewall">The use of alemtuzumab &#40;CD52-targeted agent&#41; for different diseases shows a variable risk of bacterial infection explained in part by differences in dose regiments and the presence of previous immunosuppression&#46; Overall&#44; bacterial infections are higher in some scenarios such as cutaneous lymphoma&#44; with an incidence rate of 23&#46;3 episodes per 100 patient-years&#46;<a class="elsevierStyleCrossRef" href="#bib0515"><span class="elsevierStyleSup">46</span></a></p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Immune checkpoint inhibitors&#44; cell adhesion inhibitors&#44; sphingosine-1-phosphate receptor modulators&#44; and proteasome inhibitors</span><p id="par0105" class="elsevierStylePara elsevierViewall">The available data from pivotal RCTs suggest that CTLA-4 &#40;ipilimumab or tremelimumab&#41; or PD-1&#47;PD-L1 blockade &#40;nivolumab or atezolizumab&#41; is not intrinsically associated with an increase in the risk of infection&#46;<a class="elsevierStyleCrossRefs" href="#bib0520"><span class="elsevierStyleSup">47&#8211;51</span></a> Nevertheless&#44; cancer patients receiving immune checkpoint inhibitors may develop immune-related adverse events that may entail additional immunosuppressive therapy &#40;such as corticosteroids or anti-TNF-&#945; agents&#41; impacting the susceptibility to bacterial pathogens &#40;9&#41;&#46; A systematic review in IBD found that patients treated with vedolizumab &#40;an &#945;4-integrin-targeted monoclonal antibody&#41; experienced a moderate increase in the incidence of serious bacterial infections and surgical site infections compared to placebo&#46;<a class="elsevierStyleCrossRef" href="#bib0545"><span class="elsevierStyleSup">52</span></a></p><p id="par0110" class="elsevierStylePara elsevierViewall">Pneumonia is a common bacterial infection among patients with multiple myeloma &#40;MM&#41; treated with proteasome inhibitors &#40;PIs&#41;&#44; but data do not seem to support a higher risk weighed with comparator therapies&#46; Of note&#44; untreated MM patients already face an increased incidence of respiratory tract infections &#40;including pneumonia&#41; due to the underlying impairment of humoral immune responses&#46; However&#44; this susceptibility seems to be influenced by the use of PIs in the induction regimen&#46;<a class="elsevierStyleCrossRef" href="#bib0550"><span class="elsevierStyleSup">53</span></a></p></span></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Should biologic therapies be discontinued while treating a bacterial infection&#63; When should they be reintroduced&#63;</span><p id="par0115" class="elsevierStylePara elsevierViewall">Currently&#44; studies evaluating these questions are lacking&#44; and there is no clear evidence to guide the optimal management of bacterial infections in patients receiving biologic agents&#46; Nevertheless&#44; most guidelines concur on the need of discontinuing therapy in the presence of serious bacterial infection&#44; to be reintroduced only once the infection has completely resolved&#46; The decision should ideally be taken on a case-by-case basis by an experienced physician since&#44; in some situations&#44; the abrupt withdrawal of therapy can induce a flare of the underlying autoinflammatory disorder<a class="elsevierStyleCrossRef" href="#bib0340"><span class="elsevierStyleSup">11</span></a> or negatively impact the prognosis of the underlying disease&#46; Indeed&#44; it has been reported an increased risk of progression among patients with chronic lymphocytic leukemia in which the BTK inhibitor ibrutinib has to be discontinued&#46;<a class="elsevierStyleCrossRef" href="#bib0555"><span class="elsevierStyleSup">54</span></a></p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Should asymptomatic bacteriuria be treated in patients receiving biological therapies&#63;</span><p id="par0120" class="elsevierStylePara elsevierViewall">No studies have addressed whether patients receiving biologic therapies should be systematically screened and treated for asymptomatic bacteriuria&#46; A case&#8211;control study performed in women with autoimmune rheumatic diseases reported no differences in the incidence of either asymptomatic or symptomatic urinary tract infection compared with the control group&#46;<a class="elsevierStyleCrossRef" href="#bib0560"><span class="elsevierStyleSup">55</span></a> More data are needed to establish the management in this population&#44; although systematic treatment would not be indicated&#44; in line with other clinical scenarios in which no apparent benefit from this strategy has been demonstrated&#46;<a class="elsevierStyleCrossRefs" href="#bib0565"><span class="elsevierStyleSup">56&#44;57</span></a></p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">What prevention strategies are required to prevent bacterial infections in patients receiving biological therapies&#63;</span><p id="par0125" class="elsevierStylePara elsevierViewall">Clear recommendations aimed at minimizing the risk of bacterial infection linked to the use of the different families of biological and targeted agents are mostly lacking&#44; except for some specific agents&#46; As mentioned above&#44; in view of the increased risk of <span class="elsevierStyleItalic">N&#46; meningitidis</span> infection with eculizumab use&#44; meningococcal vaccination must be assured before the initiation of therapy&#46;<a class="elsevierStyleCrossRef" href="#bib0305"><span class="elsevierStyleSup">4</span></a> Vaccination against pneumococcal disease and <span class="elsevierStyleItalic">Haemophylus influenzae</span> type B should be provided according to current guidelines&#44; and are recommended for various biologic targeted agents mentioned previously<a class="elsevierStyleCrossRefs" href="#bib0300"><span class="elsevierStyleSup">3&#44;11</span></a> &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>&#41;&#46; In other specific scenarios&#44; antibiotic prophylaxis is recommended&#44; as occurs in patients on EGFR targeted-agents who should receive oral doxycycline to prevent skin infections&#46;<a class="elsevierStyleCrossRef" href="#bib0315"><span class="elsevierStyleSup">6</span></a> However&#44; it should be emphasized that there is no clear evidence to support such practices&#44; and any potential benefit must be always balanced against the well-defined risk of inducing antimicrobial resistance&#44; as observed in neutropenic patients&#46;</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Conclusion</span><p id="par0130" class="elsevierStylePara elsevierViewall">Bacterial infections in patients on targeted and biologic therapies have a variable incidence depending on the agent used&#44; with this risk being influenced by contributing factors such as previous comorbidities&#44; the activity of the underlying condition&#44; or the receipt of additional immunosuppressive therapy&#46; There are few specific recommendations concerning the management and prevention of bacterial infections in these patient populations&#46; The proven risk of invasive infections due to encapsulated bacteria clearly supports meningococcal and pneumococcal vaccination among patients treated with eculizumab and anti-CD20 agents&#46; Nonetheless&#44; evidence is mostly lacking for therapies involving interleukins and other soluble mediators&#44; and no guidance may be provided for newer agents even in the presence of a theoretical infection risk &#40;such as that potentially resulting from the blockade of the pro-inflammatory cytokines IL-1&#946; or IL-6&#41;&#46; In addition&#44; no risk thresholds have been established to define in which patient subgroups interventions should be implemented&#46; Multicenter post-marketing surveillance with granular information on the type and severity of infection&#44; open-label extension studies and other sources of real-world data are necessary to elucidate the safety profile of these therapies&#44; with the ultimate aim to define specific interventions if significant risk signals emerge&#46;</p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Funding sources</span><p id="par0135" class="elsevierStylePara elsevierViewall">This research was supported by <span class="elsevierStyleGrantSponsor" id="gs1">Plan Nacional de I&#43;D&#43;I 2013&#8211;2016</span> and <span class="elsevierStyleGrantSponsor" id="gs2">Instituto de Salud Carlos III&#44; Subdirecci&#243;n General de Redes y Centros de Investigaci&#243;n Cooperativa</span>&#44; Spanish Ministry of Science and Innovation&#44; Spanish Network for Research in Infectious Diseases &#40;REIPI RD16&#47;0016&#47;0002&#41; &#8211; co-financed by the E<span class="elsevierStyleGrantSponsor" id="gs3">uropean Development Regional Fund &#40;EDRF&#41;</span> &#8220;<span class="elsevierStyleItalic">A way to achieve Europe&#8221;&#46;</span> M&#46;F&#46;R&#46; holds a research contract &#8220;Miguel Servet&#8221; &#40;CP 18&#47;00073&#41; from the Spanish Ministry of Science and Innovation&#44; Instituto de Salud Carlos III&#46;</p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Conflict of interest</span><p id="par0140" class="elsevierStylePara elsevierViewall">The authors have no conflicts of interests to disclose&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:13 [
        0 => array:3 [
          "identificador" => "xres1709481"
          "titulo" => "Abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec1512047"
          "titulo" => "Keywords"
        ]
        2 => array:3 [
          "identificador" => "xres1709480"
          "titulo" => "Resumen"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0010"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec1512048"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        5 => array:3 [
          "identificador" => "sec0010"
          "titulo" => "What is the risk of developing a bacterial infection with the different targeted and biological agents&#63;"
          "secciones" => array:6 [
            0 => array:2 [
              "identificador" => "sec0015"
              "titulo" => "Soluble immune effector molecules and pro-inflammatory cytokines&#58; anti-TNF-&#945; agents"
            ]
            1 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "Agents targeting interleukins&#44; immunoglobulins and complement factors"
            ]
            2 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "Cell-surface receptors and associated signaling pathways"
            ]
            3 => array:2 [
              "identificador" => "sec0030"
              "titulo" => "Intracellular signaling pathways &#40;tyrosine kinase and mTOR inhibitors&#41;"
            ]
            4 => array:2 [
              "identificador" => "sec0035"
              "titulo" => "Agents targeting lymphoid or myeloid cells surface antigens"
            ]
            5 => array:2 [
              "identificador" => "sec0040"
              "titulo" => "Immune checkpoint inhibitors&#44; cell adhesion inhibitors&#44; sphingosine-1-phosphate receptor modulators&#44; and proteasome inhibitors"
            ]
          ]
        ]
        6 => array:2 [
          "identificador" => "sec0045"
          "titulo" => "Should biologic therapies be discontinued while treating a bacterial infection&#63; When should they be reintroduced&#63;"
        ]
        7 => array:2 [
          "identificador" => "sec0050"
          "titulo" => "Should asymptomatic bacteriuria be treated in patients receiving biological therapies&#63;"
        ]
        8 => array:2 [
          "identificador" => "sec0055"
          "titulo" => "What prevention strategies are required to prevent bacterial infections in patients receiving biological therapies&#63;"
        ]
        9 => array:2 [
          "identificador" => "sec0060"
          "titulo" => "Conclusion"
        ]
        10 => array:2 [
          "identificador" => "sec0065"
          "titulo" => "Funding sources"
        ]
        11 => array:2 [
          "identificador" => "sec0070"
          "titulo" => "Conflict of interest"
        ]
        12 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2020-08-13"
    "fechaAceptado" => "2020-10-06"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec1512047"
          "palabras" => array:5 [
            0 => "Bacterial infection"
            1 => "Targeted and biological therapies"
            2 => "Immunosuppression"
            3 => "Risk"
            4 => "Incidence"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec1512048"
          "palabras" => array:5 [
            0 => "Infecci&#243;n bacteriana"
            1 => "Terapias biol&#243;gicas"
            2 => "Inmunosupresi&#243;n"
            3 => "Riesgo"
            4 => "Incidencia"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Over the past decades&#44; the advent of targeted and biological therapies has revolutionized the management of cancer and autoimmune&#44; hematological and inflammatory conditions&#46; Although a large amount of information is now available on the risk of opportunistic infections associated with some of these agents&#44; the evidence regarding the susceptibility to bacterial infections is more limited&#46; Biological agents have been shown to entail a variable risk of bacterial infections in pivotal randomized clinical trials and post-marketing studies&#46; Recommendations on risk minimization strategies and therapeutic interventions are therefore scarce and often based on expert opinion&#44; with only a few clear statements for some particular agents &#40;i&#46;e&#46; meningococcal vaccination for patients receiving eculizumab&#41;&#46; In the present review the available information regarding the incidence of and risk factors for bacterial infection associated with the use of different groups of biological agents is summarized according to their mechanisms of action&#44; and recommendations based on this evidence are provided&#46; Additional information coming from clinical research and real-world studies is required to address unmet questions in this emerging field&#46;</p></span>"
      ]
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">La introducci&#243;n de terapias dirigidas y biol&#243;gicas ha revolucionado a lo largo de las &#250;ltimas d&#233;cadas el tratamiento del c&#225;ncer y de las enfermedades autoinmunes&#44; hematol&#243;gicas e inflamatorias&#46; Si bien existe abundante informaci&#243;n acerca del exceso de riesgo de infecci&#243;n oportunista vinculado a algunos de estos agentes&#44; la evidencia disponible sobre el riesgo de infecci&#243;n bacteriana espec&#237;ficamente es m&#225;s limitada&#46; En el marco de los ensayos cl&#237;nicos pivotales y de estudios poscomercializaci&#243;n se ha demostrado un riesgo variable de infecci&#243;n bacteriana asociada al uso de terapias biol&#243;gicas&#46; Por ese motivo las recomendaciones para su minimizaci&#243;n y abordaje terap&#233;utico son escasas&#44; y a menudo basadas en la opini&#243;n de expertos&#44; con tan solo algunos escenarios de alto riesgo claramente establecidos para ciertos agentes &#40;como la recomendaci&#243;n de vacunaci&#243;n anti-meningoc&#243;cica en pacientes tratados con eculizumab&#41;&#46; En la presente revisi&#243;n se actualiza la informaci&#243;n disponible respecto a la incidencia de infecci&#243;n bacteriana relacionada con las diferentes familias terap&#233;uticas seg&#250;n su mecanismo de acci&#243;n y sus factores de riesgo&#44; aport&#225;ndose igualmente algunas recomendaciones basadas en esta evidencia&#46; Se requieren m&#225;s estudios de investigaci&#243;n cl&#237;nica en vida real para aclarar las preguntas sin resolver en este novedoso campo&#46;</p></span>"
      ]
    ]
    "multimedia" => array:2 [
      0 => array:9 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "fuente" => "Adapted from Teixeira L et al&#46;<a class="elsevierStyleCrossRef" href="#bib0340"><span class="elsevierStyleSup">11</span></a>"
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">COPD&#58; chronic obstructive pulmonary disease&#44; DMARDs&#58; disease modifying anti-rheumatic drugs&#44; RA&#58; rheumatoid arthritis&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Specific syndromes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Risk factors&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Upper or lower respiratory infections&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Advanced ageCOPD&#47;asthmaDiabetes mellitusHeart diseaseSmoking&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Urinary tract infections&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Age<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>65 yearsConcomitant therapy with corticosteroid &#40;daily prednisone dose<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>5&#8211;10<span class="elsevierStyleHsp" style=""></span>mg or equivalent&#41; or DMARDsDisease duration<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10 yearsDiabetes mellitusHeart diseaseChronic renal diseaseRecurrent infectionsCharlson comorbidity index<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>2Hypogamaglobulinemia &#40;in patients treated with anti-CD-20 agents&#41;COPD&#47;asthmaSmoking&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Skin and skin structure infections&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Advanced ageDiabetes mellitusHistory of previous skin and skin structure infectionsCorticosteroid therapy &#40;daily prednisone dose<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleHsp" style=""></span>mg or equivalent&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Osteoarticular infections&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Advanced ageProsthesisOpportunistic infectionsCorticosteroid therapy &#40;daily prednisone dose<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleHsp" style=""></span>mg or equivalent&#41;Existence of extra-articular RA manifestationsB-cell depletion&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Disseminated infection&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Advanced ageLongstanding rheumatic diseaseHistory of previous infectionsConcomitant therapy with DMARDs and glucocorticoids&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab2903187.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Risk factors for the occurrence of bacterial infections in patients with rheumatic diseases receiving biological therapy&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Table 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Hib&#58; Haemophilus influenzae type b&#59; CRBSI&#58; Catheter related bloodsttream infection&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Therapeutic group&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Specific targeted agents&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Bacterial infection risk&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Prevention strategies&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Agents targeting pro-inflammatory cytokines&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">TNF-&#945;-targeted agents&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Moderate to high<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pneumococcal vaccination&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="7" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Agents targeting interleukins&#44; immunoglobulins and complement factors</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IL-1-targeted agents&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pneumococcal vaccination&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IL-5-targeted agents&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Not increased&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IL-6&#47;IL-6R-targeted agents&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Moderate to high&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pneumococcal vaccination&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IL-12&#47;23 p40-targeted agents&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Not increased&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IL-17-targeted agents&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mild&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Not defined&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IgE-targeted agents&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Not increased&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">C5-targeted agents&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">High to specific bacteria&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Menigococcal&#44; pneumococcal and Hib vaccination&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="5" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Cell surface receptors and associated signaling pathways</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">VEGF-targeted agents&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Not defined&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">VEGFR tyrosine kinase inhibitors&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Not defined&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">EGFR -targeted agents&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">High&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Doxycycline prophylaxis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">HER2&#47;neu-targeted agents Inhibitors of ErbB tyrosine kinase family&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mild&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Not defined&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Not increased&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="8" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Intracellular signaling pathways &#40;tyrosine kinase and mTOR inhibitors&#41;</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">BRAF inhibitors&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Not increased&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">MEK inhibitors&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Not increased&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PI3K inhibitors&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Not increased&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">mTOR inhibitors&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">High<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pneumococcal vaccination&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Janus kinase &#40;JAK&#41; inhibitors&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">High&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pneumococcal vaccination&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">BCR&#47;ABL tyrosine kinase inhibitors&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Not increased&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Antiapoptotic protein Bcl-2- targeted agents&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Not established&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Bruton&#39;s tyrosine kinase inhibitors&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">High&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pneumococcal vaccination&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="10" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Agents targeting lymphoid or myeloid cells surface antigens</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">CD19-targeted agents&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Moderate &#40;CRBSI&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Not defined&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">CD20-targeted agents&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pneumococcal vaccination&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">CD22-targeted agents&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Not increased&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">CD30-targeted agents&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Not increased&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">CD33-targeted agents&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Not established&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">CD38-targeted agents&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mild&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Not defined&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">CD40-targeted agents&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mild&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Not defined&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">SLAMF7-targeted agents&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Not defined&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">CD52-targeted agents&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Not defined&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">CCR4-targeted agents&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Not increased&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Not defined&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Immune checkpoint inhibitors&#44; cell adhesion inhibitors&#44; sphingosine-1-phosphate receptor modulators&#44; and proteasome inhibitors</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PD-1&#47;PD-L1-targeted agents&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Not increased<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Related to additional immunosuppression&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">CTLA-4-targeted agents&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Not increased<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#945;4-integrins-targeted agents&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Moderate<a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">d</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Not defined&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Proteasome inhibitors&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pneumococcal vaccination&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LFA-3-targeted agents&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Not increased&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Sphingosine-1-phosphate receptor&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Not increased&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab2903188.png"
              ]
            ]
          ]
          "notaPie" => array:4 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Conflicting data&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Dose-dependent &#40;higher for cancer patients that for solid organ transplant recipients&#46;</p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0015"
              "etiqueta" => "c"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Risk may be increased due to additional immunosuppression used to treat immune-related adverse events&#46;</p>"
            ]
            3 => array:3 [
              "identificador" => "tblfn0020"
              "etiqueta" => "d"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0020">Specifically vedolizumab&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Bacterial infection risk associated to different families of targeted and biological agents and proposed prevention strategies&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:57 [
            0 => array:3 [
              "identificador" => "bib0290"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Screening for cervical and breast cancer among women with inflammatory bowel disease&#58; a population-based study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "H&#46; Singh"
                            1 => "Z&#46; Nugent"
                            2 => "A&#46;A&#46; Demers"
                            3 => "C&#46;N&#46; Bernstein"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Inflamm Bowel Dis"
                        "fecha" => "2011"
                        "volumen" => "17"
                        "paginaInicial" => "1741"
                        "paginaFinal" => "1750"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0295"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "ESCMID Study Group for Infections in Compromised Hosts &#40;ESGICH&#41; Consensus Document on the Safety of targeted and biological therapies&#58; an Infectious Diseases perspective &#40;Introduction&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Fern&#225;ndez-Ruiz"
                            1 => "Y&#46; Meije"
                            2 => "O&#46; Manuel"
                            3 => "H&#46; Akan"
                            4 => "J&#46; Carratal&#224;"
                            5 => "J&#46;M&#46; Aguado"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.cmi.2018.01.029"
                      "Revista" => array:8 [
                        "tituloSerie" => "Clin Microbiol Infect"
                        "fecha" => "2018"
                        "volumen" => "24"
                        "numero" => "Suppl&#46; 2"
                        "paginaInicial" => "S2"
                        "paginaFinal" => "S9"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29427801"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S1064748118303269"
                          "estado" => "S300"
                          "issn" => "10647481"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0300"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "ESCMID Study Group for Infections in Compromised Hosts &#40;ESGICH&#41; Consensus Document on the safety of targeted and biological therapies&#58; an Infectious Diseases perspective &#40;Soluble immune effector molecules &#91;I&#93;&#58; anti-tumor necrosis factor-&#945; agents&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;W&#46; Baddley"
                            1 => "F&#46; Cantini"
                            2 => "D&#46; Goletti"
                            3 => "J&#46;J&#46; G&#243;mez-Reino"
                            4 => "E&#46; Mylonakis"
                            5 => "R&#46; San-Juan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.cmi.2017.12.025"
                      "Revista" => array:7 [
                        "tituloSerie" => "Clin Microbiol Infect"
                        "fecha" => "2018"
                        "volumen" => "24"
                        "numero" => "Suppl&#46; 2"
                        "paginaInicial" => "S10"
                        "paginaFinal" => "S20"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29459143"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0305"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "ESCMID Study Group for Infections in Compromised Hosts &#40;ESGICH&#41; Consensus Document on the safety of targeted and biological therapies&#58; an Infectious Diseases perspective &#40;Soluble immune effector molecules &#91;II&#93;&#58; agents targeting interleukins&#44; immunoglobulins and complement factors&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K&#46;L&#46; Winthrop"
                            1 => "X&#46; Mariette"
                            2 => "J&#46;T&#46; Silva"
                            3 => "E&#46; Benamu"
                            4 => "L&#46;H&#46; Calabrese"
                            5 => "A&#46; Dumusc"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.cmi.2018.02.002"
                      "Revista" => array:7 [
                        "tituloSerie" => "Clin Microbiol Infect"
                        "fecha" => "2018"
                        "volumen" => "24"
                        "numero" => "Suppl&#46; 2"
                        "paginaInicial" => "S21"
                        "paginaFinal" => "S40"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29447987"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0310"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "ESCMID Study Group for Infections in Compromised Hosts &#40;ESGICH&#41; Consensus Document on the safety of targeted and biological therapies&#58; an Infectious Diseases perspective &#40;Cell surface receptors and associated signaling pathways&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "J&#46; Aguilar-Company"
                            1 => "M&#46; Fern&#225;ndez-Ruiz"
                            2 => "R&#46; Garc&#237;a-Campelo"
                            3 => "A&#46;C&#46; Garrido-Castro"
                            4 => "I&#46; Ruiz-Camps"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.cmi.2017.12.027"
                      "Revista" => array:7 [
                        "tituloSerie" => "Clin Microbiol Infect"
                        "fecha" => "2018"
                        "volumen" => "24"
                        "numero" => "Suppl&#46; 2"
                        "paginaInicial" => "S41"
                        "paginaFinal" => "S52"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29426804"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0315"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "ESCMID Study Group for Infections in Compromised Hosts &#40;ESGICH&#41; Consensus Document on the safety of targeted and biological therapies&#58; an Infectious Diseases perspective &#40;Intracellular signaling pathways&#58; tyrosine kinase and mTOR inhibitors&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Reinwald"
                            1 => "J&#46;T&#46; Silva"
                            2 => "N&#46;J&#46; Mueller"
                            3 => "J&#46; Fort&#250;n"
                            4 => "C&#46; Garzoni"
                            5 => "J&#46;W&#46; de Fijter"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.cmi.2018.02.009"
                      "Revista" => array:7 [
                        "tituloSerie" => "Clin Microbiol Infect"
                        "fecha" => "2018"
                        "volumen" => "24"
                        "numero" => "Suppl&#46; 2"
                        "paginaInicial" => "S53"
                        "paginaFinal" => "S70"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29454849"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0320"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "ESCMID Study Group for Infections in Compromised Hosts &#40;ESGICH&#41; Consensus Document on the safety of targeted and biological therapies&#58; an Infectious Diseases perspective &#40;Agents targeting lymphoid cells surface antigens &#91;I&#93;&#58; CD19&#44; CD20 and CD52&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Mikulska"
                            1 => "S&#46; Lanini"
                            2 => "C&#46; Gudiol"
                            3 => "L&#46; Drgona"
                            4 => "G&#46; Ippolito"
                            5 => "M&#46; Fern&#225;ndez-Ruiz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.cmi.2018.02.003"
                      "Revista" => array:7 [
                        "tituloSerie" => "Clin Microbiol Infect"
                        "fecha" => "2018"
                        "volumen" => "24"
                        "numero" => "Suppl&#46; 2"
                        "paginaInicial" => "S71"
                        "paginaFinal" => "S82"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29447988"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0325"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "ESCMID Study Group for Infections in Compromised Hosts &#40;ESGICH&#41; Consensus Document on the safety of targeted and biological therapies&#58; an infectious diseases perspective &#40;Agents targeting lymphoid or myeloid cells surface antigens &#91;II&#93;&#58; CD22&#44; CD30&#44; CD33&#44; CD38&#44; CD40&#44; SLAMF-7 and CCR4&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "L&#46; Drgona"
                            1 => "C&#46; Gudiol"
                            2 => "S&#46; Lanini"
                            3 => "B&#46; Salzberger"
                            4 => "G&#46; Ippolito"
                            5 => "M&#46; Mikulska"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.cmi.2018.03.022"
                      "Revista" => array:7 [
                        "tituloSerie" => "Clin Microbiol Infect"
                        "fecha" => "2018"
                        "volumen" => "24"
                        "numero" => "Suppl&#46; 2"
                        "paginaInicial" => "S83"
                        "paginaFinal" => "S94"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29572070"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0330"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "ESCMID Study Group for Infections in Compromised Hosts &#40;ESGICH&#41; Consensus Document on the safety of targeted and biological therapies&#58; an Infectious Diseases perspective &#40;Immune checkpoint inhibitors&#44; cell adhesion inhibitors&#44; sphingosine-1-phosphate receptor modulators and proteasome inhibitors&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46; Redelman-Sidi"
                            1 => "O&#46; Michielin"
                            2 => "C&#46; Cervera"
                            3 => "C&#46; Ribi"
                            4 => "J&#46;M&#46; Aguado"
                            5 => "M&#46; Fern&#225;ndez-Ruiz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.cmi.2018.01.030"
                      "Revista" => array:7 [
                        "tituloSerie" => "Clin Microbiol Infect"
                        "fecha" => "2018"
                        "volumen" => "24"
                        "numero" => "Suppl&#46; 2"
                        "paginaInicial" => "S95"
                        "paginaFinal" => "S107"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29427804"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0335"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Frequency of infection in patients with rheumatoid arthritis compared with controls&#58; a population-based study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "M&#46;F&#46; Doran"
                            1 => "C&#46;S&#46; Crowson"
                            2 => "G&#46;R&#46; Pond"
                            3 => "W&#46;M&#46; O&#8217;Fallon"
                            4 => "S&#46;E&#46; Gabriel"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Arthritis Rheum"
                        "fecha" => "2002"
                        "volumen" => "46"
                        "paginaInicial" => "2287"
                        "paginaFinal" => "2293"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0340"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "management of infections in rheumatic patients receiving biological therapies&#46; The Portuguese Society of rheumatology recommendations"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L&#46; Teixeira"
                            1 => "A&#46;R&#46; Fonseca"
                            2 => "G&#46; Eug&#233;nio"
                            3 => "M&#46; Rodrigues"
                            4 => "N&#46; Khmelinskii"
                            5 => "S&#46; Fernandes"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Acta Reumatol Port"
                        "fecha" => "2016"
                        "volumen" => "2016"
                        "paginaInicial" => "287"
                        "paginaFinal" => "304"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0345"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;R&#46; Curtis"
                            1 => "S&#46; Yang"
                            2 => "N&#46;M&#46; Patkar"
                            3 => "L&#46; Chen"
                            4 => "J&#46;A&#46; Singh"
                            5 => "G&#46;W&#46; Cannon"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Arthritis Care Res"
                        "fecha" => "2014"
                        "volumen" => "66"
                        "paginaInicial" => "990"
                        "paginaFinal" => "997"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0350"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Risk of hospitalization for serious bacterial infections in patients with rheumatoid arthritis treated with biologics&#46; Analysis from the record study of the Italian society for rheumatology"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "G&#46; Carrara"
                            1 => "A&#46; Bortoluzzi"
                            2 => "G&#46; Sakellariou"
                            3 => "M&#46; Govoni"
                            4 => "C&#46;A&#46; Scir&#232;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Exp Rheumatol"
                        "fecha" => "2019"
                        "volumen" => "37"
                        "paginaInicial" => "60"
                        "paginaFinal" => "66"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30148440"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0355"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients&#58; a multicenter retrospective cohort study in Japan"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; Mori"
                            1 => "T&#46; Yoshitama"
                            2 => "T&#46; Hidaka"
                            3 => "F&#46; Sakai"
                            4 => "M&#46; Hasegawa"
                            5 => "Y&#46; Hashiba"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1371/journal.pone.0179179"
                      "Revista" => array:5 [
                        "tituloSerie" => "PLOS ONE"
                        "fecha" => "2017"
                        "volumen" => "12"
                        "paginaInicial" => "1"
                        "paginaFinal" => "16"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0360"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Risk of serious infection in biological treatment of patients with rheumatoid arthritis&#58; a systematic review and meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;A&#46; Singh"
                            1 => "C&#46; Cameron"
                            2 => "S&#46; Noorbaloochi"
                            3 => "T&#46; Cullis"
                            4 => "M&#46; Tucker"
                            5 => "R&#46; Christensen"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(14)61704-9"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2015"
                        "volumen" => "386"
                        "paginaInicial" => "258"
                        "paginaFinal" => "265"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25975452"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0365"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease&#58; a systematic review and network meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "S&#46; Bonovas"
                            1 => "G&#46; Fiorino"
                            2 => "M&#46; Allocca"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.cgh.2016.04.039"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Gastroenterol Hepatol"
                        "fecha" => "2016"
                        "volumen" => "14"
                        "paginaInicial" => "1385"
                        "paginaFinal" => "1397"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27189910"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0370"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Askling"
                            1 => "C&#46;M&#46; Fored"
                            2 => "L&#46; Brandt"
                            3 => "E&#46; Baecklund"
                            4 => "L&#46; Bertilsson"
                            5 => "N&#46; Feltelius"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/ard.2006.062760"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2007"
                        "volumen" => "66"
                        "paginaInicial" => "1339"
                        "paginaFinal" => "1344"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17261532"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0375"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Anakinra&#44; a recombinant human interleukin-1 receptor antagonist &#40;r-metHuIL-1ra&#41;&#44; in patients with rheumatoid arthritis&#58; a large&#44; international&#44; multicenter&#44; placebo-controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46;M&#46; Fleischmann"
                            1 => "J&#46; Schechtman"
                            2 => "R&#46; Bennett"
                            3 => "M&#46;L&#46; Handel"
                            4 => "G&#46;R&#46; Burmester"
                            5 => "J&#46; Tesser"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.10870"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Rheum"
                        "fecha" => "2003"
                        "volumen" => "48"
                        "paginaInicial" => "927"
                        "paginaFinal" => "934"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12687534"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0380"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Observational study on efficacy&#44; safety&#44; and drug survival of anakinra in rheumatoid arthritis patients in clinical practice"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "A&#46;A&#46; Den Broeder"
                            1 => "E&#46; De Jong"
                            2 => "M&#46;J&#46;A&#46;M&#46; Franssen"
                            3 => "M&#46;E&#46;C&#46; Jeurissen"
                            4 => "M&#46; Flendrie"
                            5 => "F&#46;H&#46;J&#46; Van Den Hoogen"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/ard.2004.033662"
                      "Revista" => array:7 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2006"
                        "volumen" => "65"
                        "paginaInicial" => "760"
                        "paginaFinal" => "762"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16269431"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0165178114003886"
                          "estado" => "S300"
                          "issn" => "01651781"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0385"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Safety of extended treatment with anakinra in patients with rheumatoid arthritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46; Fleischmann"
                            1 => "J&#46; Tesser"
                            2 => "M&#46;H&#46; Schiff"
                            3 => "J&#46; Schechtman"
                            4 => "G&#46;R&#46; Burmester"
                            5 => "R&#46; Bennett"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/ard.2005.048371"
                      "Revista" => array:7 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2006"
                        "volumen" => "65"
                        "paginaInicial" => "1006"
                        "paginaFinal" => "1012"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16396977"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0165032714004492"
                          "estado" => "S300"
                          "issn" => "01650327"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0390"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis &#40;MONARCH&#41;&#58; a randomised&#44; double-blind&#44; parallel-group phase III trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46;R&#46; Burmester"
                            1 => "Y&#46; Lin"
                            2 => "R&#46; Patel"
                            3 => "J&#46; Van Adelsberg"
                            4 => "E&#46;K&#46; Mangan"
                            5 => "N&#46;M&#46;H&#46; Graham"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/annrheumdis-2016-210310"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2017"
                        "volumen" => "76"
                        "paginaInicial" => "840"
                        "paginaFinal" => "847"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27856432"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0395"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "ROUTINE-a prospective&#44; multicentre&#44; non-interventional&#44; observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46; Iking-Konert"
                            1 => "U&#46; Von Hin&#252;ber"
                            2 => "C&#46; Richter"
                            3 => "H&#46; Schwenke"
                            4 => "I&#46; G&#252;rtler"
                            5 => "P&#46; K&#228;stner"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Rheumatology &#40;United Kingdom&#41;"
                        "fecha" => "2016"
                        "volumen" => "55"
                        "paginaInicial" => "624"
                        "paginaFinal" => "635"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0400"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Integrated safety in tocilizumab clinical trials"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "M&#46;H&#46; Schiff"
                            1 => "J&#46;M&#46; Kremer"
                            2 => "A&#46; Jahreis"
                            3 => "E&#46; Vernon"
                            4 => "J&#46;D&#46; Isaacs"
                            5 => "R&#46;F&#46; van Vollenhoven"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:3 [
                        "tituloSerie" => "Arthritis Res Ther"
                        "fecha" => "2011"
                        "volumen" => "13"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0405"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effectiveness and safety of tocilizumab&#58; postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46; Koike"
                            1 => "M&#46; Harigai"
                            2 => "S&#46; Inokuma"
                            3 => "N&#46; Ishiguro"
                            4 => "J&#46; Ryu"
                            5 => "T&#46; Takeuchi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3899/jrheum.130466"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Rheumatol"
                        "fecha" => "2014"
                        "volumen" => "41"
                        "paginaInicial" => "15"
                        "paginaFinal" => "23"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24187110"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0410"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Secukinumab long-term safety experience&#58; a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "P&#46;C&#46;M&#46; Van De Kerkhof"
                            1 => "C&#46;E&#46;M&#46; Griffiths"
                            2 => "K&#46; Reich"
                            3 => "C&#46;L&#46; Leonardi"
                            4 => "A&#46; Blauvelt"
                            5 => "T&#46;F&#46; Tsai"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2016.03.024"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "2016"
                        "volumen" => "75"
                        "paginaInicial" => "83"
                        "paginaFinal" => "98"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27180926"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0415"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Infections from 7 clinical trials of Ixekizumab an anti-interleukin-17A monoclonal antibody in patients with moderate-to-severe psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K&#46;A&#46; Papp"
                            1 => "H&#46; Bachelez"
                            2 => "A&#46; Blauvelt"
                            3 => "K&#46;L&#46; Winthrop"
                            4 => "R&#46; Romiti"
                            5 => "M&#46; Ohtsuki"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Br J Dermatol"
                        "fecha" => "2017"
                        "volumen" => "167"
                        "paginaInicial" => "1537"
                        "paginaFinal" => "1551"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0420"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Risk of serious infection with biologic and systemic treatment of psoriasis&#58; results from the psoriasis longitudinal assessment and registry &#40;PSOLAR&#41;&#46; JAMA Dermatology"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46;E&#46; Kalb"
                            1 => "D&#46;F&#46; Fiorentino"
                            2 => "M&#46;G&#46; Lebwohl"
                            3 => "J&#46; Toole"
                            4 => "Y&#46; Poulin"
                            5 => "A&#46;D&#46; Cohen"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "fecha" => "2015"
                        "volumen" => "151"
                        "paginaInicial" => "961"
                        "paginaFinal" => "969"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0425"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bevacizumab increases the risk of infections in cancer patients&#58; a systematic review and pooled analysis of 41 randomized controlled trials"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "W&#46;X&#46; Qi"
                            1 => "S&#46; Fu"
                            2 => "Q&#46; Zhang"
                            3 => "X&#46;M&#46; Guo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.critrevonc.2015.02.007"
                      "Revista" => array:6 [
                        "tituloSerie" => "Crit Rev Oncol Hematol"
                        "fecha" => "2015"
                        "volumen" => "94"
                        "paginaInicial" => "323"
                        "paginaFinal" => "336"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25749417"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0430"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effects and side effects of using sorafenib and sunitinib in the treatment of metastatic renal cell carcinoma"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "C&#46;R&#46; Hansen"
                            1 => "D&#46; Grimm"
                            2 => "J&#46; Bauer"
                            3 => "M&#46; Wehland"
                            4 => "N&#46;E&#46; Magnusson"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "Int J Mol Sci"
                        "fecha" => "2017"
                        "volumen" => "18"
                        "paginaInicial" => "E461"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib0435"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy &#40;REVEL&#41;&#58; a multicentre&#44; double-blind&#44; randomised phase 3 trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "E&#46;B&#46; Garon"
                            1 => "T&#46;E&#46; Ciuleanu"
                            2 => "O&#46; Arrieta"
                            3 => "K&#46; Prabhash"
                            4 => "K&#46;N&#46; Syrigos"
                            5 => "T&#46; Goksel"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(14)60845-X"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2014"
                        "volumen" => "384"
                        "paginaInicial" => "665"
                        "paginaFinal" => "673"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24933332"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib0440"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Meta-analysis of individual patient safety data from six randomized&#44; placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "D&#46; Arnold"
                            1 => "C&#46;S&#46; Fuchs"
                            2 => "J&#46; Tabernero"
                            3 => "A&#46; Ohtsu"
                            4 => "A&#46;X&#46; Zhu"
                            5 => "E&#46;B&#46; Garon"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/annonc/mdx514"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Oncol"
                        "fecha" => "2017"
                        "volumen" => "28"
                        "paginaInicial" => "2932"
                        "paginaFinal" => "2942"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28950290"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib0445"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab&#58; a systematic review and meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "T&#46; Funakoshi"
                            1 => "M&#46; Suzuki"
                            2 => "K&#46; Tamura"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ctrv.2014.09.002"
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer Treat Rev"
                        "fecha" => "2014"
                        "volumen" => "40"
                        "paginaInicial" => "1221"
                        "paginaFinal" => "1229"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25288497"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib0450"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients&#58; a systematic review and meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "W&#46;X&#46; Qi"
                            1 => "S&#46; Fu"
                            2 => "Q&#46; Zhang"
                            3 => "X&#46;M&#46; Guo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/s12916-014-0231-1"
                      "Revista" => array:6 [
                        "tituloSerie" => "BMC Med"
                        "fecha" => "2014"
                        "volumen" => "12"
                        "paginaInicial" => "1"
                        "paginaFinal" => "12"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25539784"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib0455"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Infection risk in breast cancer patients treated with trastuzumab&#58; a systematic review and meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "T&#46; Funakoshi"
                            1 => "M&#46; Suzuki"
                            2 => "H&#46;B&#46; Muss"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Breast Cancer Res Treat"
                        "fecha" => "2015"
                        "volumen" => "149"
                        "paginaInicial" => "321"
                        "paginaFinal" => "330"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib0460"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;C&#46; Byrd"
                            1 => "R&#46;R&#46; Furman"
                            2 => "S&#46;E&#46; Coutre"
                            3 => "I&#46;W&#46; Flinn"
                            4 => "J&#46;A&#46; Burger"
                            5 => "K&#46;A&#46; Blum"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1215637"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2013"
                        "volumen" => "369"
                        "paginaInicial" => "32"
                        "paginaFinal" => "42"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23782158"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib0465"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;L&#46; Wang"
                            1 => "S&#46; Rule"
                            2 => "P&#46; Martin"
                            3 => "A&#46; Goy"
                            4 => "R&#46; Auer"
                            5 => "B&#46;S&#46; Kahl"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1306220"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2013"
                        "volumen" => "369"
                        "paginaInicial" => "507"
                        "paginaFinal" => "516"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23782157"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            36 => array:3 [
              "identificador" => "bib0470"
              "etiqueta" => "37"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Three-year efficacy&#44; safety&#44; and survival findings from COMFORT-II&#44; a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:5 [
                            0 => "F&#46; Cervantes"
                            1 => "A&#46;M&#46; Vannucchi"
                            2 => "J&#46;-J&#46; Kiladjian"
                            3 => "H&#46;K&#46; Al-Ali"
                            4 => "A&#46; Sirulnik"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Blood"
                        "fecha" => "2013"
                        "volumen" => "122"
                        "paginaInicial" => "4047"
                        "paginaFinal" => "4053"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            37 => array:3 [
              "identificador" => "bib0475"
              "etiqueta" => "38"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Attributable risk of infection to mTOR inhibitors everolimus and temsirolimus in the treatment of cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "C&#46;A&#46; Garcia"
                            1 => "S&#46; Wu"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/07357907.2016.1242009"
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer Invest"
                        "fecha" => "2016"
                        "volumen" => "34"
                        "paginaInicial" => "521"
                        "paginaFinal" => "530"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27791402"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            38 => array:3 [
              "identificador" => "bib0480"
              "etiqueta" => "39"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "H&#46; Kantarjian"
                            1 => "A&#46; Stein"
                            2 => "N&#46; G&#246;kbuget"
                            3 => "A&#46;K&#46; Fielding"
                            4 => "A&#46;C&#46; Schuh"
                            5 => "J&#46;-M&#46; Ribera"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1609783"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2017"
                        "volumen" => "376"
                        "paginaInicial" => "836"
                        "paginaFinal" => "847"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28249141"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            39 => array:3 [
              "identificador" => "bib0485"
              "etiqueta" => "40"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Blinatumomab treatment of older adults with relapsed&#47;refractory B-precursor acute lymphoblastic leukemia&#58; results from 2 phase 2 studies"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "H&#46;M&#46; Kantarjian"
                            1 => "A&#46;S&#46; Stein"
                            2 => "R&#46;C&#46; Bargou"
                            3 => "C&#46; Grande Garcia"
                            4 => "R&#46;A&#46; Larson"
                            5 => "M&#46; Stelljes"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/cncr.30031"
                      "Revista" => array:7 [
                        "tituloSerie" => "Cancer"
                        "fecha" => "2016"
                        "volumen" => "122"
                        "paginaInicial" => "2178"
                        "paginaFinal" => "2185"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27143254"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0140673610619976"
                          "estado" => "S300"
                          "issn" => "01406736"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            40 => array:3 [
              "identificador" => "bib0490"
              "etiqueta" => "41"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Complete hematologic and molecular response in adult patients with relapsed&#47;refractory philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab&#58; results from a phase II&#44; single-arm&#44; multicenter study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46; Martinelli"
                            1 => "N&#46; Boisel"
                            2 => "P&#46; Chevalier"
                            3 => "Ottman o"
                            4 => "N&#46; G&#252;kbuget"
                            5 => "M&#46;S&#46; Topp"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2016.69.3531"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol"
                        "fecha" => "2017"
                        "volumen" => "35"
                        "paginaInicial" => "1795"
                        "paginaFinal" => "1802"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28355115"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            41 => array:3 [
              "identificador" => "bib0495"
              "etiqueta" => "42"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Safety and tolerability of an anti-CD19 monoclonal antibody&#44; MEDI-551&#44; in subjects with systemic sclerosis&#58; a phase I&#44; randomized&#44; placebo-controlled&#44; escalating single-dose study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "E&#46; Schiopu"
                            1 => "S&#46; Chatterjee"
                            2 => "V&#46; Hsu"
                            3 => "A&#46; Flor"
                            4 => "D&#46; Cimbora"
                            5 => "K&#46; Patra"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/s13075-016-1021-2"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Res Ther"
                        "fecha" => "2016"
                        "volumen" => "18"
                        "paginaInicial" => "1"
                        "paginaFinal" => "14"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26732314"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            42 => array:3 [
              "identificador" => "bib0500"
              "etiqueta" => "43"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Risk of infection in patients with lymphoma receiving rituximab&#58; systematic review and meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "S&#46; Lanini"
                            1 => "A&#46;C&#46; Molloy"
                            2 => "P&#46;E&#46; Fine"
                            3 => "A&#46;G&#46; Prentice"
                            4 => "G&#46; Ippolito"
                            5 => "C&#46;C&#46; Kibbler"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/1741-7015-9-36"
                      "Revista" => array:5 [
                        "tituloSerie" => "BMC Med"
                        "fecha" => "2011"
                        "volumen" => "9"
                        "paginaInicial" => "36"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21481281"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            43 => array:3 [
              "identificador" => "bib0505"
              "etiqueta" => "44"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Longterm safety of rituximab&#58; Final report of the rheumatoid arthritis global clinical trial program over 11 years"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "R&#46;F&#46; Van Vollenhoven"
                            1 => "R&#46;M&#46; Fleischmann"
                            2 => "D&#46;E&#46; Furst"
                            3 => "S&#46; Lacey"
                            4 => "P&#46;B&#46; Lehane"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3899/jrheum.150051"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Rheumatol"
                        "fecha" => "2015"
                        "volumen" => "42"
                        "paginaInicial" => "1761"
                        "paginaFinal" => "1766"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26276965"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            44 => array:3 [
              "identificador" => "bib0510"
              "etiqueta" => "45"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Infections in non-splenectomized persistent or chronic primary immune thrombocytopenia adults&#58; risk factors and vaccination effect"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "G&#46; Moulis"
                            1 => "M&#46; Lapeyre-Mestre"
                            2 => "A&#46; Palmaro"
                            3 => "L&#46; Sailler"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jth.13622"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Thromb Haemost"
                        "fecha" => "2016"
                        "volumen" => "15"
                        "paginaInicial" => "785"
                        "paginaFinal" => "791"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28078756"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            45 => array:3 [
              "identificador" => "bib0515"
              "etiqueta" => "46"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Spectrum of infection&#44; risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "K&#46;A&#46; Thursky"
                            1 => "L&#46;J&#46; Worth"
                            2 => "J&#46;F&#46; Seymour"
                            3 => "H&#46; Miles Prince"
                            4 => "M&#46;A&#46; Slavin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2141.2005.05789.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Haematol"
                        "fecha" => "2006"
                        "volumen" => "132"
                        "paginaInicial" => "3"
                        "paginaFinal" => "12"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16371014"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            46 => array:3 [
              "identificador" => "bib0520"
              "etiqueta" => "47"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Ipilimumab monotherapy in patients with pretreated advanced melanoma&#58; a randomised&#44; double-blind&#44; multicentre&#44; phase 2&#44; dose-ranging study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;D&#46; Wolchok"
                            1 => "B&#46; Neyns"
                            2 => "G&#46; Linette"
                            3 => "S&#46; Negrier"
                            4 => "J&#46; Lutzky"
                            5 => "L&#46; Thomas"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S1470-2045(09)70334-1"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet Oncol"
                        "fecha" => "2010"
                        "volumen" => "11"
                        "paginaInicial" => "155"
                        "paginaFinal" => "164"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20004617"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            47 => array:3 [
              "identificador" => "bib0525"
              "etiqueta" => "48"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The safety of anti PD-1 therapeutics for the treatment of melanoma"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "E&#46; Ramelyte"
                            1 => "S&#46;A&#46; Schindler"
                            2 => "R&#46; Dummer"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/14740338.2016.1248402"
                      "Revista" => array:6 [
                        "tituloSerie" => "Expert Opin Drug Saf"
                        "fecha" => "2017"
                        "volumen" => "16"
                        "paginaInicial" => "41"
                        "paginaFinal" => "53"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27737598"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            48 => array:3 [
              "identificador" => "bib0530"
              "etiqueta" => "49"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "safety and activity of anti-PD-L1 antibody in patients with advanced cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;R&#46; Brahmer"
                            1 => "S&#46;S&#46; Tykodi"
                            2 => "L&#46;Q&#46;M&#46; Chow"
                            3 => "W&#46;-J&#46; Hwu"
                            4 => "S&#46;L&#46; Topalian"
                            5 => "P&#46; Hwu"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1200694"
                      "Revista" => array:7 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2012"
                        "volumen" => "366"
                        "paginaInicial" => "2455"
                        "paginaFinal" => "2465"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22658128"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0165178116304504"
                          "estado" => "S300"
                          "issn" => "01651781"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            49 => array:3 [
              "identificador" => "bib0535"
              "etiqueta" => "50"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer &#40;POPLAR&#41;&#58; a multicentre&#44; open-label&#44; phase 2 randomised controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L&#46; Fehrenbacher"
                            1 => "A&#46; Spira"
                            2 => "M&#46; Ballinger"
                            3 => "M&#46; Kowanetz"
                            4 => "J&#46; Vansteenkiste"
                            5 => "J&#46; Mazieres"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(16)00587-0"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2016"
                        "volumen" => "387"
                        "paginaInicial" => "1837"
                        "paginaFinal" => "1846"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26970723"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            50 => array:3 [
              "identificador" => "bib0540"
              "etiqueta" => "51"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma&#58; a randomised dose-comparison cohort of a phase 1 trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46; Robert"
                            1 => "A&#46; Ribas"
                            2 => "J&#46;D&#46; Wolchok"
                            3 => "F&#46;S&#46; Hodi"
                            4 => "O&#46; Hamid"
                            5 => "R&#46; Kefford"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(14)60958-2"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2014"
                        "volumen" => "384"
                        "paginaInicial" => "1109"
                        "paginaFinal" => "1117"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25034862"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            51 => array:3 [
              "identificador" => "bib0545"
              "etiqueta" => "52"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Systematic review&#58; the safety of vedolizumab for the treatment of inflammatory bowel disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "W&#46;A&#46; Bye"
                            1 => "V&#46; Jairath"
                            2 => "S&#46;P&#46;L&#46; Travis"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/apt.14075"
                      "Revista" => array:7 [
                        "tituloSerie" => "Aliment Pharmacol Ther"
                        "fecha" => "2017"
                        "volumen" => "46"
                        "paginaInicial" => "3"
                        "paginaFinal" => "15"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28449273"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S1525505016000755"
                          "estado" => "S300"
                          "issn" => "15255050"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            52 => array:3 [
              "identificador" => "bib0550"
              "etiqueta" => "53"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma &#40;ENDEAVOR&#41;&#58; and randomised&#44; phase 3&#44; open-label&#44; multicentre study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;A&#46; Dimopoulos"
                            1 => "P&#46; Moreau"
                            2 => "A&#46; Palumbo"
                            3 => "D&#46; Joshua"
                            4 => "L&#46; Pour"
                            5 => "R&#46; H&#225;jek"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S1470-2045(15)00464-7"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet Oncol"
                        "fecha" => "2016"
                        "volumen" => "17"
                        "paginaInicial" => "27"
                        "paginaFinal" => "38"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26671818"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            53 => array:3 [
              "identificador" => "bib0555"
              "etiqueta" => "54"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "K&#46;J&#46; Maddocks"
                            1 => "A&#46;S&#46; Ruppert"
                            2 => "G&#46; Lozanski"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamaoncol.2014.218"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA Oncol"
                        "fecha" => "2015"
                        "volumen" => "1"
                        "paginaInicial" => "80"
                        "paginaFinal" => "87"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26182309"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            54 => array:3 [
              "identificador" => "bib0560"
              "etiqueta" => "55"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Asymptomatic bacteriuria in women with autoimmune rheumatic disease&#58; prevalence&#44; risk factors&#44; and clinical significance"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;P&#46; Georgiadou"
                            1 => "M&#46;N&#46; Gamaletsou"
                            2 => "I&#46; Mpanaka"
                            3 => "A&#46; Vlachou"
                            4 => "A&#46;V&#46; Goules"
                            5 => "D&#46;C&#46; Ziogas"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Clin Infect Dis"
                        "fecha" => "2015"
                        "volumen" => "60"
                        "paginaInicial" => "868"
                        "paginaFinal" => "874"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            55 => array:3 [
              "identificador" => "bib0565"
              "etiqueta" => "56"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Maternal and neonatal consequences of treated and untreated asymptomatic bacteriuria in pregnancy&#58; a prospective cohort study with an embedded randomised controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "B&#46;M&#46; Kazemier"
                            1 => "F&#46;N&#46; Koningstein"
                            2 => "C&#46; Schneeberger"
                            3 => "A&#46; Ott"
                            4 => "P&#46;M&#46; Bossuyt"
                            5 => "E&#46; de Miranda"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S1473-3099(15)00070-5"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet Infect Dis"
                        "fecha" => "2015"
                        "volumen" => "15"
                        "paginaInicial" => "1324"
                        "paginaFinal" => "1333"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26255208"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            56 => array:3 [
              "identificador" => "bib0570"
              "etiqueta" => "57"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Should asymptomatic bacteriuria be systematically treated in kidney transplant recipients&#63; Results from a randomized controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Orig&#252;en"
                            1 => "F&#46; L&#243;pez-Medrano"
                            2 => "M&#46; Fern&#225;ndez-Ruiz"
                            3 => "N&#46; Polanco"
                            4 => "E&#46; Guti&#233;rrez"
                            5 => "E&#46; Gonz&#225;lez"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ajt.13829"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Transplant"
                        "fecha" => "2016"
                        "volumen" => "16"
                        "paginaInicial" => "2943"
                        "paginaFinal" => "2953"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27088545"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/2529993X/0000004000000005/v1_202205140740/S2529993X22000879/v1_202205140740/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "63563"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Review article"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/2529993X/0000004000000005/v1_202205140740/S2529993X22000879/v1_202205140740/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529993X22000879?idApp=UINPBA00004N"
]

Article information

ISSN: 2529993X
Original language: English

DOI:10.1016/j.eimce.2020.10.014

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 November	2	0	2
2024 October	16	5	21
2024 September	12	8	20
2024 August	12	10	22
2024 July	20	3	23
2024 June	18	2	20
2024 May	13	7	20
2024 April	14	3	17
2024 March	16	6	22
2024 February	25	5	30
2024 January	11	2	13
2023 December	11	2	13
2023 November	21	3	24
2023 October	29	1	30
2023 September	12	0	12
2023 August	22	0	22
2023 July	12	2	14
2023 June	24	3	27
2023 May	41	0	41
2023 April	39	0	39
2023 March	34	0	34
2023 February	18	5	23
2023 January	8	5	13
2022 December	10	3	13
2022 November	18	9	27
2022 October	2	2	4

Show all

Indexed in:

Follow us:

Subscribe:

Statistics

Indexed in:

Follow us:

Subscribe:

Statistics

Subscribe to our newsletter